Annual Report 2022 RHÖN-KLINIKUM AG

OUR MISSION Our Mission RHÖN‐KLINIKUM AG is one of the largest healthcare providers in Germany. We offer excellent medical care with a direct tie-in to universities and research facilities. With our campus approach we are setting standards for a cross-sector medical and therapeutic care – and that not just in rural areas. Our five maximum- and intermediate-care hospital sites – Campus Bad Neustadt, Klinikum Frankfurt (Oder), Giessen and Marburg University Hospitals as well as Zentralklinik Bad Berka – are attractive employers and training centres. People from over 70 nations work there for our Company. Our activities are underpinned by common values such as integrity, responsibility, compassion, care and respect. Sustainability is an essential part of our identity. It is a reflection of how we create a sound environment for our patients, employees, business partners and investors. At the same time, it enables us to safeguard our success on a sustainable basis. RHÖN-KLINIKUM AG | Annual Report 2022 RHÖN-KLINIKUM AG | Annual Report 2022 1 1

LETTER TO SHAREHOLDERS But we will also be taking on new challenges, supported with appropriate investments. In addition to advances in medicine, we will handle the tasks of digitalisation and transformation of the healthcare delivery landscape by promoting specialisation whilst at the same time expanding outpatient medicine through comprehensive and targeted investments. We will further strengthen the firm foundation in healthcare delivery for research and teaching. Above all, patients will benefit from this commitment to their region as provision with cutting-edge medical care for them is safeguarded. But our employees at both sites in Marburg and Giessen will, of course, also benefit since they will continue to enjoy secure and attractive jobs. All stakeholders are agreed and firmly convinced that UKGM can look ahead to good prospects for the long term. As the third-largest university hospital in Germany, it provides excellent medical care as well as research services and is the heart of our healthcare Company. Its unique public mandate coupled with private entrepreneurship is and remains the foundation and guarantor of its success. Setting standards – shaping the future Recent years and 2022 in particular were anything but good for Germany’s hospitals. They were dominated by the efforts to cope with the pandemic, an excessive workload, increasing shortages not only in qualified staff but also any staff, as well as exploding material and energy costs. Almost 60 per cent of hospitals are operating in the red. After having faced a difficult hospital sector and overall economic environment, we look back on a financially solid, albeit challenging, financial year. How much more economic pressure will bear down on the healthcare system which (DRGs or no DRGs) will mainly be determined by the financial situation of the statutory health insurance funds? How will we cope with the huge shortage of qualified staff? And will the aftershocks of the COVID-19 pandemic with persistently declining case numbers and wave after wave of staffing absences push us to the limits of our capabilities? These are the really big issues and challenges that we must continue to grapple with. And this situation is further exacerbated by inflation, war and the energy crisis. Not a few (specialist) hospitals will have to close down due to the huge cost pressures and the impact of the planned hospital reform. Coming on top of that are the massive cost hikes hospitals face for energy, medical goods or services which they cannot refinance. It will take many different structural changes to maintain the efficiency of the healthcare system, but it will also take the new forms of healthcare delivery and regional healthcare networks that have been under discussion for so long. RHÖN-KLINIKUM AG | Annual Report 2022 3

LETTER TO SHAREHOLDERS Economic performance in 2022 At RHÖN-KLINIKUM AG, financial year 2022 was marked by the response to the COVID-19 pandemic, efforts to cope with inflation, the energy crisis, supply problems, and the impacts of the war in Ukraine. We are now also facing new challenges from taking in and providing medical care to refugees and injured people, the energy and procurement crisis as well as the steep increase in purchasing prices. Despite the considerable obstacles faced as a result of the pandemic, we treated roughly 855,000 patients on an inpatient and outpatient basis at our facilities. This is a slight increase of 9,691 patients, or 1.1 per cent, compared with financial year 2021. Although this trend is encouraging, our most pressing task is nonetheless to improve the trend in service volumes at our hospitals. Having exceeded our financial targets for 2022, we have therefore adjusted our earnings forecast. Consolidated EBITDA is 105.6 million euros and thus 4.4 million euros above the previous year’s level; revenues stand at 1.4 billion euros. The figures show a positive trend and confirm that we are heading in the right direction with our strategic measures. We now have to consistently work on our targets by ensuring that the hospitals concentrate on their core activities, by expanding outpatient care structures and by optimising our processes. Exploiting opportunities – acting sustainably Sustainability and environmental protection are fundamental issues of our times to which we are committed. Modern hospital operations need a lot of energy – whether for the state-of-the-art building technology, the wide array of medical devices or increasing digitalisation. To ensure energy-optimised operations for this, we invest in sustainable technologies at all our sites. Our focus and concern in this regard is also to reduce CO₂, waste volumes and water consumption without compromising on the safety and comfort of the care we provide to our patients. As we look ahead to the huge potential the future holds, one thing is clear: any problems – no matter how big – always bring opportunities. The real challenge here is discovering and exploiting them. Dear Shareholders, Our Company has a highly qualified team that is committed to tackling all challenges. Also in 2022, that is something we have demonstrated in the difficult environment we have faced. I would like to thank you for the trust you put in us and am counting on your continued interest in RHÖN-KLINIKUM AG. Stay well. Yours sincerely, Prof. Dr Tobias Kaltenbach Chairman of the Board of Management RHÖN-KLINIKUM Aktiengesellschaft Bad Neustadt a. d. Saale, March 2023 RHÖN-KLINIKUM AG | Annual Report 2022 5

REPORT OF THE SUPERVISORY BOARD As chairman of the Supervisory Board, I also engaged in a regular exchange of information and ideas with all members of the Board of Management – also between meetings held by the corporate bodies – and was kept thoroughly informed at all times about material developments and current business transactions. We thoroughly discussed the resolution proposals made by the Board of Management in the Supervisory Board committee responsible for the respective items and/or the Supervisory Board plenary session and, to the extent required by statute, the Articles of Association and the Terms of Reference, gave our opinion on the same after a careful review. Where required in the case of particu- larly pressing and time-critical business matters, the Supervisory Board, or, as the case may be, the competent committee also adopted resolutions by voting in written form. Moreover, in view of the ongoing risks of COVID-19 infections, various meetings were conducted as fully virtual meetings in the form of a video confer- ence in financial year 2022. Work of the Supervisory Board in the plenary session In financial year 2022 a total of seven (four ordinary and three extraordinary) meetings of the Supervisory Board plenary session were held; moreover, four written resolutions were adopted by the plenary session of the Supervisory Board. The members of the Board of Management attended the meetings of the Supervisory Board except in those cases of agenda items relating to internal issues and matters of the Supervisory Board and matters pertaining to the Board of Management. Two of the seven meetings of the Supervisory Board plenary session were conducted as fully virtual meetings (by video/telephone conference). Information on the composition of the Supervisory Board and the committees as well as attendance of the individual members in the meetings can be found in the overview at the end of this Report. At the meetings of the Supervisory Board the plenary session, based on detailed reports of the Board of Management on current developments, strategic issues and the financial position of the Group, as well as based on the written reports and presentations by the Board of Management, regularly deliberated together with the Board of Management on the net assets, financial position and results of operations, the trend in revenues and earnings, the performance data, key figures and human resources of the Company and Group as well as of the individual Group subsidiar- ies. The Supervisory Board moreover, together with the Board of Management, examined the impact of the COVID-19 pandemic on the business performance and the hospitals of the RHÖN- KLINIKUM Group as well as the stage reached in negotiations with the representatives of the Hesse State Government on the granting of investment funding for UKGM in a follow-on agreement. This follow-on agreement was to replace the “agreement on the implementation of the white paper for the further development of university medicine in Central Hesse” (Zukunftspapier für die Weiterentwicklung der hessischen Universitätsmedizin) in effect since 2017 between RHÖN-KLINIKUM Aktiengesellschaft, Universitäts- klinikum Gießen und Marburg GmbH (UKGM), the Universities of Giessen and Marburg (along with their respective faculty of medicine) and the Federal State of Hesse. The Board of Manage- ment moreover informed on current developments in healthcare policy, the healthcare environment, healthcare legislation and their impact on the Group as well as the competitive situation. The respective interim reports for the past quarters were explained by the Board of Management in detail in the plenary session prior to publication. In an extraordinary Supervisory Board meeting on 1 February 2022 – the first meeting of the financial year – the Supervisory Board thoroughly examined the Letter of Intent signed by the Board of Management on 14 January 2022 on the granting of investment funding by the Federal State of Hesse for UKGM and approved the same. The key points agreed in the Letter of Intent were then to be transposed into a binding follow-on agreement in the course of 2022. In addition, the Supervisory Board adopted various adjustments to the respective Terms of Reference of the Board of Management and Supervisory Board and voted to pro- pose Dr Cornelia Süfke to succeed Ms Nicole Mooljee Damani as member of the Supervisory Board at the Annual General Meeting of RHÖN-KLINIKUM Aktiengesellschaft. At the balance sheet meeting on 23 March 2022, which was also attended by KPMG AG Wirtschaftsprüfungsgesellschaft (KPMG) ( as statutory auditor for financial year 2021, we thoroughly discussed in the plenary session – after a statement given by the Audit Committee – together with the Board of Management the annual financial statements and management report of RHÖN-KLINIKUM Aktiengesellschaft as well as the consolidated financial statements and the Group management report for financial year 2021. The auditor reported on the essential findings and results of the audits and were available to us for questions and additional information. The plenary session approved both the annual financial statements and the consolidated financial statements. After the Supervisory Board completed its own review, the separate condensed non- financial report for 2021 reviewed by KPMG was moreover approved. In addition, the Supervisory Board resolved to support the Board of Management’s proposal for the appropriation of net distributable profit for financial year 2021. Lastly, the Supervisory Board looked at the Report of the Board of Management on Relations to Affiliates (dependent company report) and resolved – on recommendation by the Audit Committee – that no objections were to be raised against the declaration made by the Board of Management at the end of the report. Furthermore, the Super- visory Board approved the Declaration on Corporate Governance RHÖN-KLINIKUM AG | Annual Report 2022 7

current member of the Board of Management, Prof. Dr Griewing, under which Prof. Dr Griewing was to leave the Board of Manage- ment in his function as CMO (Chief Medical Officer) and assume the position of a Generally Authorised Representative. At the ordinary meeting on 15 December 2022 the Board of Man- agement, referring to the public announcement on 5 December 2022 regarding the breakthrough in the negotiations with the Federal State of Hesse on the granting of investment funding to UKGM, reported that a new white paper on the further cooperation and coverage of investment requirements of UKGM for the next ten years would soon be concluded. According to the report of the Board of Management, the understanding on the key points reached at the beginning of December 2022 was to be transposed into a binding agreement by the end of February 2023; to preclude any gap in the provisions, the existing agreements with the Federal State of Hesse were moreover, and contrary to the notice of termination already given in June 2022, prolonged until the end of February 2023 at the latest. The Supervisory Board further deliberated jointly with the Board of Management on the current trend in service volumes as at 30 November 2022 as well as the current developments in human resources and wages. Moreover, the Supervisory Board examined the preliminary economic and investment planning for financial year 2023. At this meeting the Supervisory Board also examined the adjustment of the regular issuing of the Declaration of Compliance pursuant to section 161 of the German Stock Corporation Act (Aktiengesetz, AktG) for implementing the recommendations and suggestions as set out in the German Corporate Governance Code (GCGC) (for further details, see “Corporate Governance and Issue of the Declaration of Compliance”). Work of the Supervisory Board in the committees With a view to performing its tasks and assuming its responsibility in the best possible way, the Supervisory Board has set up standing committees whose members possess specific expertise and experience for the special issues dealt with in the committees. REPORT OF THE SUPERVISORY BOARD The committees prepare resolutions and issues to be decided in the plenary session of the Supervisory Board. They act as bodies with power to pass resolutions within the scope prescribed by law, the Articles of Association – also in lieu of the Supervisory Board – and the Terms of Reference of the latter to the extent consistent with statute and previously defined by the Supervisory Board. The committees generally meet separately from plenary sessions. Meet- ings were also held as conference calls convened on short notice or in the form of a video conference as required. At three meetings held in each case by video conference, the Personnel Affairs Committee prepared subjects relating to personnel matters of the Board of Management for the Supervisory Board and, to the extent required, adopted resolutions and accord- ingly made recommendations to the Supervisory Board on the adoption of resolutions. During the past financial year, the Mediation Committee (pur- suant to section 27 (3) of the Co-Determination Act (MitBestG)) did not meet. The Audit Committee of the Supervisory Board met four times during the year under review, with all meetings having been held by video conference. All meetings were attended by represen- tatives of the Board of Management. One meeting was attended by the statutory auditor for financial year 2021, KPMG. At another meeting, KPMG attended as auditor for the review of the interim report for the first half of financial year 2022. The Audit Committee notably was responsible for review and preliminary consultation for the RHÖN-KLINIKUM Aktiengesell schaft consolidated annual financial statements for financial year 2021. The Audit Committee assessed the independence of KPMG designated as statutory auditor to audit the consolidated financial statements and the Group management report as well as the annual financial statements and the management report for financial year 2022 and to conduct the review of the half-year financial report, obtained the statement regarding the auditor’s independence, recommended to the plenary session of the Supervisory Board a proposal for the election of the auditor to be submitted to the Annual General Meeting and – after the election – issued the statutory auditor with the audit assignment and concluded with it a reasonable fee agreement for the same. The Audit Committee also defined the areas of emphasis of the audit of the 2022 annual financial statements that were to be considered by KPMG beyond the statutory audit scope. RHÖN-KLINIKUM AG | Annual Report 2022 9

REPORT OF THE SUPERVISORY BOARD Self-evaluation of the Supervisory Board The effectiveness and efficiency of the bodies of a German stock corporation are decisive for a company’s market success and sustainable development. The GCGC therefore underscores the importance of a regular review of the work of the supervisory board. The supervisory board is required to ask and answer ques- tions of relevance for the performance of its supervisory duties and to discuss such issues jointly to ensure that the supervisory board can carry out its work properly and on a sustainable basis. The relevant questions include the structure of the supervisory body as well as its committees, the appointment of supervisory board members as well as its procedures for regular cooperation. Moreover, it is essential to ensure effective communication between the supervisory board and the board of management and promote the role of the supervisory board members as repre senting the shareholders and employees with regard to the company’s objectives and the resulting challenges. In this context, the Supervisory Board of RHÖN-KLINIKUM Aktien- gesellschaft, with the assistance of a law firm, conducted a structured survey of the Supervisory Board members during the period from the end of 2021 to the end of February 2022. The period of the self-evaluation covered the work of the Supervisory Board from the 2020 Annual General Meeting. The objective was to analyse the work of the Supervisory Board and on that basis develop recommendations for the future work of the Supervisory Board of RHÖN-KLINIKUM Aktiengesellschaft. The feedback was therefore systematically assessed and then presented and discussed by the chairman of the Supervisory Board in the plenary session at the meeting on 8 June 2022. Overall, the survey revealed a positive picture of the work performed by the Super- visory Board; at the same time, however, some issues showing room for improvement in terms of the cooperation and work in the body and its committees were also identified. The findings obtained have since been taken into account by the full Super- visory Board, the committees as well as by the Supervisory Board chairman and committee chairpersons in their work. Corporate Governance and issue of the Declaration of Compliance Pursuant to section 161 AktG, the management board and super- visory board of a German exchange-listed stock corporation are required to state each year in a Declaration of Compliance to what extent the company complies with the recommendations of the GCGC and where it deviates from such recommendations. In November 2022, the Supervisory Board of RHÖN-KLINIKUM Aktiengesellschaft had approved the Declaration of Compliance prepared by the Audit Committee. Subsequently, the Declaration of Compliance had therefore been regularly revised and replaced by a Declaration of Compliance issued on 17 November 2022 by the Board of Management and the Supervisory Board. Since the Declaration of Compliance is always to be issued in the same month as the previous year and the last ordinary meeting of the Supervisory Board of RHÖN-KLINIKUM Aktiengesellschaft in 2023 is due to be held in the month of December, the Supervisory Board, at its meeting on 15 December 2022, updated the Declar- ation of Compliance once again – with a content identical to the Declaration of Compliance of 17 November 2022. Examination and approval of the 2022 financial statements The Board of Management adopted the financial statements of the Company and the management report for the year ended 31 December 2022 in accordance with the provisions of the HGB, while the consolidated financial statements as at 31 December 2022 and Group management report for financial year 2022 were adopted pursuant to section 315e HGB in accordance with the principles set out in the International Financial Reporting Standards (IFRS). The auditor, KPMG, examined the annual financial statements and the management report of the Company for financial year 2022 as well as the consolidated financial statements and Group management report for financial year 2022. The statutory auditor issued an unqualified auditor’s report in each case. RHÖN-KLINIKUM AG | Annual Report 2022 11

REPORT OF THE SUPERVISORY BOARD Composition of the Board of Management and changes in the Board of Management Pursuant to section 7 (1) of the Company’s Articles of Association, the Board of Management is made up of three persons unless expressly stipulated otherwise by the Supervisory Board. By expiry of 31 October 2022, the Board of Management of RHÖN-KLINIKUM Aktiengesellschaft was composed of four persons – Dr Christian Höftberger, Dr Stefan Stranz, Dr Gunther K. Weiß and Prof. Dr Bernd Griewing. As a result of personnel changes on the Board of Management (in this regard see “Work of the Supervisory Board in the plenary session” above), the Board of Management of the Company has now been made up of only three persons since 1 November 2022: Prof. Dr Tobias Kaltenbach (CEO), Dr Stefan Stranz (CFO) and Dr Gunther K. Weiß (COO). The personal details, functions and duties of the individual members of the Board of Management are presented in detail under the heading “Corporate bodies of the Company”. Composition of the Supervisory Board and changes in the Supervisory Board Pursuant to Section 10 (1) of the Articles of Association of RHÖN-KLINIKUM Aktiengesellschaft in conjunction with the requirements of the Co-Determination Act (MitBestG), the Super- visory Board of RHÖN-KLINIKUM Aktiengesellschaft is comprised of 16 members. Eight Supervisory Board members are elected by the shareholders and eight Supervisory Board members by the employees. In accordance with section 96 (2) AktG, at least 30 per cent of the Supervisory Board is to be made up of women and at least 30 per cent of men, which – relative to the entire Super- visory Board – corresponds to at least five seats in each case. The minimum share must be met by the Supervisory Board as a whole, since neither the shareholder nor employee representatives raised any objections regarding the issue of overall compliance. After Nicole Mooljee Damani left the Supervisory Board with effect from 8 January 2022, the Local Court (Amts- gericht) of Schweinfurt by decision of 2 March 2022 appoint- ed Dr Cornelia Süfke as member of the Supervisory Board of the Company. Dr Süfke was then elected as member of the Supervisory Board by the Annual General Meeting on 8 June 2022 for the period until conclusion of the Annual General Meeting resolving on formal approval of actions for financial year 2024. The personal details of the members of the Supervisory Board in 2022 are set out in the notes to the consolidated financial statements. The section also provides information on the pro- fessional qualifications of the Supervisory Board members as well as their further mandates. The organisational structure of the Supervisory Board and the composition of the committees during the past financial year are set out in the overview pro- vided following this Report. The Supervisory Board thanks the members of the Board of Management, all employees of the Group as well as the employee representatives of all Group companies for their tremendous commitment and work performed during the past financial year which presented huge challenges for everyone. The Supervisory Board Dr Jan Liersch Chairman Bad Neustadt a. d. Saale, 29 March 2023 RHÖN-KLINIKUM AG | Annual Report 2022 13

REPORT OF THE SUPERVISORY BOARD 2. Composition of the standing committees Personnel Affairs Committee Chairman Dr Jan Liersch Nomination Committee Chairman Dr Jan Liersch Members Number of meetings: 3 Members Peter Ducke Kai Hankeln Dr Jan Liersch Dr Thomas Pillukat Mediation Committee Chairman Dr Jan Liersch Attendance 3 3 3 3 100% 100% 100% 100% Kai Hankeln Dr Jan Liersch Hafid Rifi Committee for Decisions on Related-Party Transactions Chairman Dr Jan Liersch Number of meetings: 0 Attendance Members Number of meetings: 0 Members Attendance Number of meetings: 0 Attendance Nicole Mooljee Damani (until 8 January 2022) Irmtraut Gürkan (from 23 March 2022) Dr Jan Liersch Oliver Salomon Georg Schulze Kai Hankeln Dr Jan Liersch Dr Thomas Pillukat Georg Schulze Audit Committee Chairman Hafid Rifi Members Peter Berghöfer Regina Dickey Prof. Dr Leopold Eberhart Irmtraut Gürkan Dr Jan Liersch Hafid Rifi Number of meetings: 4 Attendance 4 4 4 4 4 4 100% 100% 100% 100% 100% 100% Medical Innovation and Quality Committee The Supervisory Board dissolved the Medical Innovation and Quality Committee by resolution of 23 March 2022. Before its dissolution, the Committee did not hold any meetings during financial year 2022. RHÖN-KLINIKUM AG | Annual Report 2022 15

THE RHÖN-KLINIKUM SHARE Performance of stock markets Compared with the RHÖN share, the German leading index DAX® declined in 2022 by 12.3 per cent to close the stock market year at 13,924 points. Other comparison indices likewise saw a disproportion- ately moderate performance against the RHÖN share. The second-tier index SDAX® fell by 27.3 per cent and closed the stock market year at 11,926 points. During the same period, the European leading index DJ EURO STOXX 50® gave up 11.9 per cent. The benchmark index for European stocks from the healthcare industry, DJ EURO STOXX Healthcare®, witnessed a 16.9 per cent decline. DE0007042301 RHK 167,406,175 66,962,470 01.01.–31.12.2022 01.01.–31.12.2021 15.30 16.20 13.00 31.12.2022 1,024.53 14.38 16.30 14.30 31.12.2021 962.92 RHÖN-KLINIKUM SHARE ISIN Ticker symbol Share capital (€) Number of shares Share prices (€) Closing price High Low Market capitalisation (€ m) Shareholder structure According to the notifications of voting rights made pursuant to section 33 et seq. of the German Securities Trading Act (Wertpapier handelsgesetz, WpHG), the shareholder structure of RHÖN-KLINIKUM AG is as follows. SHAREHOLDER STRUCTURE OF RHÖN-KLINIKUM AG In % C: 0.04 B: 6.58 A: AMR Holding GmbH, Dr Bernard große Broermann B: Free float C: Treasury stock A: 93.38 As at 31 December 2022 (on the basis of the most recent notification of voting rights to the company) RHÖN-KLINIKUM AG | Annual Report 2022 17

Corporate Social Responsibility Report Sustainability management and organisation Patients Employees Compliance Environmental protection Supplier management 21 32 39 45 47 52 RHÖN-KLINIKUM AG | Annual Report 2022 RHÖN-KLINIKUM AG | Annual Report 2022 19 19

CORPORATE RESPONSIBILITY | Corporate Social Responsibility Report | Sustainability management and organisation Corporate Social Responsibility Report SUSTAINABILITY MANAGEMENT AND ORGANISATION For us, sustainability has long been firmly established as part of our corporate strategy. Environmental, governance and social matters are just as important to us as issues from the medical world. Sustainability as an integral part of our corporate strategy | We do not understand sustainability as just something that is “nice to have” but rather as being an integral part of the corporate strategy of RHÖN-KLINIKUM AG. That is why all members of the Board of Manage- ment deal with this in their work whilst ensuring that all aspects of this subject are continuously enhanced and promoted within the Company. As a healthcare group, we embrace our medical, ecological and social responsibility. | Another way in which we define ourselves and the goals we strive to achieve is by expecting each employee of RHÖN -KLINIKUM AG to act with integrity at all times. In this regard, the principles of conduct of our Corporate Code set out both the conduct of all employees amongst themselves and the relationship between employees and patients. In addition, continuously updated Group-level works council agreements between the Board of Management and the employee representatives ensure the personal integrity of our employees in their relationship with external entities. Our sustainability reporting | The present Corporate Social Responsibility Report (CSR Report) includes the separate condensed Non-Financial Report (NFR) in accordance with sections 315b, 315c in conjunction with sections 289b to 289e of the German Commercial Code (Handelsgesetzbuch, HGB). RHÖN -KLINIKUM AG thus fulfils the reporting requirements of the German Commercial Code both at the Company level and the Group level. Unless otherwise indicated, all information stated refers to the parent (AG or joint stock corporation) and the Group equally. Above and beyond the statutory requirements, we voluntarily report on specific employee issues as well as on supplier management. | In our sustainability reporting the term “Asklepios Group” refers to those companies that belong to the corporate group of Asklepios Kliniken GmbH & Co. KGaA. The term “Asklepios” refers to Asklepios Kliniken GmbH & Co. KGaA. The abbreviation “UKGM” as used in the following refers to the university hospital corporate entity Universitäts- klinikum Gießen und Marburg GmbH. We do not understand sustainability as just something that is ‘nice to have’ but rather as being an integral part of the corporate strategy of RHÖN-KLINIKUM AG. RHÖN-KLINIKUM AG | Annual Report 2022 21

CORPORATE RESPONSIBILITY | Corporate Social Responsibility Report | Sustainability management and organisation Based on the previous year, we updated and supplemented the impact analysis for 2022 in a working group made up of numerous specialist departments and representatives from our subsidiaries. The following taxonomy-eligible economic activities were identified as a result of the analysis: Taxonomy-aligned economic activities | For the review of taxonomy compliance, the following approach ECONOMIC ACTIVITY was taken: 3.3 4.29 4.30 7.1 7.2 7.3 7.4 7.6 Economic activity Type of economic activity Manufacture of low carbon technologies for transport Electricity generation from fossil gaseous fuels High-efficiency co-generation of heat/cool and power from fossil gaseous fuels Construction of new buildings Renovation of existing buildings Installation, maintenance and repair of energy efficiency equipment Installation, maintenance and repair of charging stations for electric vehicles in buildings (and parking spaces attached to buildings) Installation, maintenance and repair of renewable energy technologies Hybrid vehicles Cogeneration plants (CHPs) Cogeneration plants (CHPs) Construction of new paediatric and juvenile psychiatry clinic at Marburg site Incl. refurbishment of administrative building at Bad Neustadt site Installation and replacement of energy-efficient light sources; installation of air conditioning system Charging stations for electric vehicles Photovoltaic system – Review of compliance with the technical screening criteria with regard to each economic activity classified as taxonomy-eligible – Review of fulfilment of requirements for minimum safeguards | After that, in addition to the degree of taxonomy eligibility, the degree of taxonomy conformity of the identified economic activities was determined and presented using the mandatory templates. The above taxonomy-eligible economic activities for 2022 were assigned to the environmental target “climate change mitigation”. To avoid double counting, plausibility tests were performed when preparing the CapEx and OpEx key performance indicators. For example, in the area of construction expenditures new construction projects were viewed separately from refurbishment projects and individual measures. The key performance indicators are based on the accounting methods used in financial reporting. In the event of uncertainties regarding the interpretation of terms and expressions used in the EU Taxonomy Regulation and in the Delegated Acts, the additional publications of the EU Commission in the form of FAQs and also the “Questions and Answers” published by the IDW were used as orientation. RHÖN-KLINIKUM AG | Annual Report 2022 23

CORPORATE RESPONSIBILITY | Corporate Social Responsibility Report | Sustainability management and organisation DNSH criteria (“Do No Significant Harm”) Climate change mitigation Climate change adaptation Water and marine resources Circular economy Pollution Biodiversity and ecosystems Minimum safeguards Taxonomy- aligned OpEx share, year N Taxonomy- aligned OpEx share, year N-1 Category (enabling activities) Category (transitional activities) Y/N Y/N Y/N Y/N Y/N Y/N Y/N % % – – – – – – – 0 0 0 0 0 0 E – – – T – – – RHÖN-KLINIKUM AG | Annual Report 2022 25

CORPORATE RESPONSIBILITY | Corporate Social Responsibility Report | Sustainability management and organisation DNSH criteria (“Do No Significant Harm”) Climate change mitigation Climate change adaptation Water and marine resources Circular economy Pollution Biodiversity and ecosystems Minimum safeguards Taxonomy- aligned CapEx share, year N Taxonomy- aligned CapEx share, year N-1 Category (enabling activities) Category (transitional activities) Y/N Y/N Y/N Y/N Y/N Y/N Y/N % % Y Y Y Y – – – Y – Y 0.0 0.0 T E E RHÖN-KLINIKUM AG | Annual Report 2022 27

CORPORATE RESPONSIBILITY | Corporate Social Responsibility Report | Sustainability management and organisation DNSH criteria (“Do No Significant Harm”) Climate change mitigation Climate change adaptation Water and marine resources Circular economy Pollution Biodiversity and ecosystems Minimum safeguards Taxonomy- aligned OpEx share, year N Taxonomy- aligned OpEx share, year N-1 Category (enabling activities) Category (transitional activities) Y/N Y/N Y/N Y/N Y/N Y/N Y/N % % E T RHÖN-KLINIKUM AG | Annual Report 2022 29

CORPORATE RESPONSIBILITY | Corporate Social Responsibility Report | Sustainability management and organisation Non-financial risks | The Board of Management of RHÖN-KLINIKUM AG has implemented a Group-wide risk management system to detect imminent risks early on and to specifically counter them in a systematic process. At the same time, our risk management function relates not only to financial risks but also all manner of risks within the Company. We regard the risk to the life and health of our patients potentially resulting from a medical intervention as the greatest risk. | RHÖN-KLINIKUM AG has implemented risk reduction measures. On a net view of risks (including COVID-19), no risks were identified that are very likely to have a serious adverse impact on these aspects. | For detailed information on our risk management and our material risks, including those in connection with non-financial aspects, please see section Opportunities and Risk Report of our Group Management Report. Our stakeholders | Our patients and their well-being are always our first priority. That is why their feedback is especially important to us. But maintaining a continuous dialogue with our other stakeholders – i.e. patients’ relatives, (potential) employees, the general public, the shareholders and investors, as well as the members of our network – is also important to us. | You will find further information on patient communication in the section Patients on the following pages of this Report. | FORMS OF DIALOGUE WITHIN STAKEHOLDER ENVIRONMENT Employee magazine WIR Social media Internet Internal newsletters Intranet Press releases Trade fairs Citizens’ events Conferences Open house Magazines General public (Potential) employees E-learning Partnerships with schools and universities Social media Recruiting events and drives Company events Internet Conference calls Presentations Press releases Conferences Annual General Meeting Shareholders and investors Patients and relatives Network partners Social media Internet Magazines Brochures Patient events Patient surveys Seeking personal contact through Management Project managers, etc. Head physicians RHÖN-KLINIKUM AG | Annual Report 2022 31

CORPORATE RESPONSIBILITY | Corporate Social Responsibility Report | Patients | MEDICAL BOARD – ADVISORY BODY MADE UP OF TOP-RANKING PHYSICIANS Neuromedicine Oncology Cardiovascular Medicine Musculoskeletal Surgery Laboratory Medicine MEDICAL BOARD Anaesthesia Emergency Medical Care Intensive Medical Care Hygiene Psychiatry/ Psychosomatics expert panels and directors of the various sites. As a new area of focus in the four expert panels of Oncology, Musculoskeletal, Cardiovascular Medicine and Neuromedicine, the representation of the potential of outpatient medicine of the specialist disciplines was elaborated, which is likewise presented by the cost and performance controlling department. As in the previous year, our management of the COVID- 19 pandemic or the analysis of scientific studies was on the agenda. | Following the strategic harmonisation of the medical bodies with the Asklepios Group, each expert panel was expanded in 2021 by two to three members from various Asklepios hospitals. This has helped to enhance Group-wide networking of medical experts and knowledge transfer. During the reporting period, the number of expert panels remained unchanged at ten. The “Quality Management and Clinical Risk Management Forum” established in 2021 met regularly. The meet- ings promoted a greater exchange of information amongst the group divisions and contributed to harmonisation and especially to ensur- ing the greatest possible safety for patients and employees within the Asklepios Group. Efforts to further ramp up collaboration with the Asklepios Group – also with digital assistance | During the reporting period just ended, we steadily enhanced our strategic collaboration with the Asklepios Group. We already work to- gether constructively in many areas – for example, when it comes to reporting on medical quality and the use of software for ensuring and enhancing patient safety. The CIRS software we use for internal critical incident reporting allows us to report and respond to critical incidents and to create a comparison basis within the Asklepios Group. | In the course of 2022, we made the necessary preparations to conduct the patient satisfaction survey uniformly at all sites as of Janu- ary 2023 and create comparability within the Asklepios Group. All sites are now using a uniform questionnaire based on the one used by the Asklepios Group. The procedure was also harmonised and has been followed continuously throughout the entire corporate group since 1 January 2023. RHÖN-KLINIKUM AG | Annual Report 2022 33

CORPORATE RESPONSIBILITY | Corporate Social Responsibility Report | Patients Forging ahead with digitalisation | Medical excellence can only be achieved if we avail ourselves of all available technical support means and always ensure that our equip- ment is state-of-the-art. | For example, we succeeded in enhancing the area of teleder- matology over the reporting period. The dermatology unit of the University Hospital of Marburg offers its teleconsulting service to the acute clinic of the RHÖN-KLINIKUM Campus Bad Neustadt and to the psychoso matic clinics. Through the fast, digital exchange of data and the involvement of the experts from Marburg University, we save precious time in the treatment process and thus improve the quality of diagnosis and care. Despite the physical distance separating them, the Marburg dermatologists are in direct contact with the patient and assist their colleagues with diagnosis and therapy. A bi-weekly tele- medical consultation was set up specifically for this purpose. Images and data are exchanged and discussed amongst the doctors via live video transmission, for example, in an electronic visit made right at the patient’s bedside. Any photos and relevant information relating to the patient can be sent in advance. At the end of 2021, a new technical platform was installed at the University Hospital of Marburg and the related equipment installed at the hospital in Bad Neustadt. In 2022, the teleconsulting service was used for the first time by an external partner. | We have also made further progress with our sekTOR -HF project launched in the middle of 2020. It brings a significant improvement in the treatment of patients suffering from left ventricular failure. The goal is to reduce the mortality rate and hospital referrals through optimum care and coordinated collaboration amongst all service providers – such as GPs or specialists, hospitals, specialist post-care providers – whilst at the same time raising the quality of life of patients suffering from cardiac failure. The patient and telemedicine play an active role in this. In a training course, each participant learns how to send his or her vital signs or details about their current state of health via app or Internet portal to the competent doctors and a network contact. If monitoring reveals any anomalies, this app can define specifically adapted measures and coordinate individual treatment recommenda- tions with the physicians involved. At the same time, another goal we are pursuing with the sekTOR-HF project is to establish a cross-sector care model by which the underlying processes can thus be coordinated and remunerated on a new basis. 50 medical practices with 220 pa- tients have since become part of sekTOR-HF. The project, which is fund- ed by the Joint Federal Committee (JFC), was presented at the Annual Conference of the European Health Management Association (EHMA) in June 2022 in Brussels and was met with great interest on the part of the conference participants. | The feedback from the various sekTOR-HF users has been very positive. In a survey from the summer of 2022, patients, doctors and Medical excellence can only be achieved if we avail ourselves of all available technical sup- port means and always ensure that our equip- ment is state-of-the-art. heart failure nurses responded to questions regarding the potential and challenges of using a telemedicine platform for telemonitoring for heart failure patients. Criteria for the survey, which were used for a university thesis, were the satisfaction with and acceptance of the platform, the influence on patient empowerment, and changes in communication, coordination and continuity. | In addition to a high standard in the quality of its medical services, a good hospital is characterised by exemplary communication with its patients and a comprehensive service offering. We are continuously striving to increasingly excel in both criteria. For example, in 2022 we continued the “Gesundheitsblog” (health blog) dealing with themes specifically tailored to patients. To measure patient satisfaction, a digital survey was introduced from 1 January 2023. We offer our patients cutting-edge medical care | RHÖN-KLINIKUM AG enjoys a high standing in the medical com- munity. In 2022, the Company once again received awards for the research findings and treatment methods of our hospitals. | The inventory of medical equipment both at the Frankfurt (Oder) healthcare campus and at our Zentralklinik Bad Berka facility was expanded with the introduction of another innovative medical equip- ment unit, the state-of-the-art “da Vinci X” ER robot. The “machine surgeon” satisfies our high quality standards for patient care and underscores our openness to innovative cutting-edge technology. RHÖN-KLINIKUM AG | Annual Report 2022 35

CORPORATE RESPONSIBILITY | Corporate Social Responsibility Report | Patients | Coronary heart disease – i.e. the narrowing of the coronary arter- ies – is a global problem and continues to be a leading cause of death in Germany. The centre of interventional cardiology at the University Hospital of Giessen began specialising in these complex procedures many years ago. With the introduction of the new treatment method of orbital atherectomy (Diamondback 360 System) introduced throughout Hessen in 2022, the portfolio at the university hospital’s heart catheter laboratory is now being expanded. | Detecting heart failure in at-risk patients at the early stage and thus improving their prognosis and quality of life is the objective of the MRI Truck that was parked on the Klinikum Frankfurt (Oder) healthcare campus for the first time on 3 June 2022. This enabled members of the health insurance fund AOK to undergo a free heart checkup. The initia- tive is to be repeated at regular intervals. The project, which is run in collaboration with and under the medical management of the German Heart Institute Berlin (DHZB), also receives funding from the German government’s Innovation Fund of the Joint Federal Committee (JFC). | On 23 February 2022, the company Bayer AG awarded for the tenth time the PHILOS Prize for initiatives supporting people with haemophilia to cope with the challenges they have to face daily. One concept launched at the University Hospital of Giessen and focusing on both medical support and individual psychosocial assistance needs was awarded the PHILOS Prize in the Inclusion and Integration category. | Construction of a training track for wheelchair users located right next to the paraplegic centre and clinic of paraplegiology/neurourol- ogy at Zentralklinik Bad Berka has been underway since July 2022. For roughly 80,000 euros, the Erfurt-based wheelchair user association ROLLIS e. V. is building the roughly 500-square-metre training facility with support from the Manfred Sauer Foundation and Zentralklinik Bad Berka. We train in the simulation room and not in the OR | Since 2007, our employees have been able to train for treatment procedures in the simulation centre at RHÖN-KLINIKUM Campus Bad Neustadt. Since then efforts have been made to significantly increase space and staffing capacities. Since 2007, our employees have been able to train for treatment procedures in the simulation centre at RHÖN-KLINIKUM Campus Bad Neustadt. Here the training offering includes anaesthesia, emergency care, car- diac and trauma surgery, as well as obstetrics and even (emergency) care for newborns. Doctors, nursing staff and therapists complete training to treat patients facing life-threatening situations and learn how to work together as a team. The simulation centre thus makes an important contribution towards greater patient safety and a higher quality of medical care. RHÖN Quality Concept | With our RHÖN Quality Concept we are pursuing the goal of steadi- ly improving our medical quality through a comprehensive approach. It is a key tool for further enhancing patient safety. Together with the Quality division of Asklepios Group, we have implemented our strategy and worked towards harmonising subjects throughout the Group in the quality management and clinical risk management areas. RHÖN-KLINIKUM AG | Annual Report 2022 37

CORPORATE RESPONSIBILITY | Corporate Social Responsibility Report | Employees EMPLOYEES They are the backbone of our success – motivated, healthy and efficient employees with outstanding qualifications. They make it possible to keep our clinical operations running and are our most valuable assets. That is why we give top priority to being attentive to our employees’ needs, as can be clearly seen from our health management approach. RHÖN -KLINIKUM AG’s attractiveness as an employer is further enhanced by its comprehensive offering of further, continued and higher-qualification training for its employees. Group are also to be harmonised. This will especially apply to manage- ment training concepts. This will make our young talent feel part of a coherent and unified corporate group from the outset. Our strategic collaboration makes us a viable and attractive employer | The strategic collaboration, pooling our know-how and mutual transfer of knowledge between RHÖN-KLINIKUM AG and the Asklepios Group make us more resilient to the impacts of the ongoing Coronavirus pandemic, the war in Ukraine and the energy and economic crisis, as well as the many different challenges we face as a result of healthcare policy, e.g. increasing regulation, a growing documentation workload and increasing outpatientisation. RHÖN-KLINIKUM AG is established as an independent employer brand. By working in close collaboration we have expanded our continued training and employee advisory services and now post job offers across the entire corporate group. | For years we have been committed to excellent medical care, competence and know-how as well as maintaining a close relation- ship based on a human approach. As an established hospital operator within a strong parent group, we enjoy an excellent reputation as an employer. We have a high level of digitalisation, act responsibly and have a highly efficient and sound structure. As a corporate group with a network of hospitals, we offer good opportunities for personal advancement. That is something that is particularly valued by doctors in Germany. As attractive large intermediate- and maximum-care fa- cilities with access to university medicine, our hospitals have a unique selling point. | With 18,140 employees, we are one of Germany’s biggest health- care groups. During financial year 2022, we have taken a variety of measures to recruit new, qualified staff. Thanks to the strategic collab- oration with the Asklepios Group from the second half of 2020, the range of opportunities we can offer has grown further. Together, we have developed and implemented some concepts we hope will make us even more attractive as an employer. These include the Fürsten- berg company’s Employee Assistance Programme (EAP) that we have introduced throughout the Group. Our human resources management | Our two-tier organisation and human resources management ap- proach has once again proven itself during the 2022 reporting period. Each of our hospitals has its own human resources department that reports to the respective hospital management. Under this decentralised structure, operative decisions producing the best outcomes for the hos- pital site can be made. By contrast, any strategically important decisions are made centrally with the involvement of Group Human Resources. At the Group level, all issues of fundamental importance are pooled, such as questions relating to the orientation of the Group’s human resources policy and establishment and promotion of the employer branding concept. Here we always maintain a close dialogue with the Asklepios Group. This has led to further professionalisation and improvement in HR management. Our collaboration is based on trust and on promot- ing increasingly close ties. In the previous year, we have also come up with a sensible way of harmonising the various bonus and employee benefits programmes. | Since the end of 2022, we have been using the new e-learning soft- ware procured in the previous year together with the Asklepios Group. It features learning structures and combined with in-person learning enables us to implement our strategy of “blended learning”. With the computer system we can also provide pre-defined mandatory training courses for specific employee groups. By the end of the first quarter of 2023, the trainee programmes of RHÖN-KLINIKUM AG and the Asklepios RHÖN-KLINIKUM AG | Annual Report 2022 39

CORPORATE RESPONSIBILITY | Corporate Social Responsibility Report | Employees of their current difficulties. At the end of the reporting period, we evaluated the level of use of the programme for the Frankfurt (Oder) as well as Giessen and Marburg sites since the EAP has already been offered there for roughly one year. Staff having used the programme report a very high level of satisfaction with it. Frequently, employees also reach out for help to prevent mental health issues and stress- related health risks as well as the related problems of work perfor- mance and sickness-related absences. | Moreover, the EAP is specifically used to train executive staff, HR departments and works councils in managing employees dealing with psychological stress and addiction-related problems. | Lastly, we have noticed that the EAP has helped some employees better identify with the Company whilst boosting their motivation and, as a result, also their performance. | Employees may have an individual consultation at the hospi- tal premises, by phone or by video conference via a specific pass- word-protected Internet link with our partner Fürstenberg Institut. | Furthermore, the offering of resilience training was significantly expanded and rolled out at additional sites. Focus on our employees’ work-life balance | We realise that keeping a work-life balance is also of key im- portance when it comes to maintaining stable mental and physical health. That is why we see it as our duty to create the environment in which our employees can succeed in harmonising their professional and personal life. We achieve this by ensuring the most flexible work- ing hours possible and the provisions introduced for our employees to perform their work under trust-based, flextime or part-time schemes. In 2022, 7,888 employees (roughly 43.5 per cent) were employed part-time. We have entered into individual agreements for each site in which we take greater account of employees’ personal priorities. In this regard, we have adopted clear staffing backup rules, try to take personal requests into account and have established an on-call service or stand-in employee pools. Whenever possible, we also allow our employees to work in a mobile office. | Some of these measures are developed, implemented and of- fered in close collaboration with healthcare funds and occupational insurance agencies, including in 2022, for example, the course “Ge- sund führen” (healthy managing) offered for executive staff at both sites of the University Hospitals of Giessen and Marburg. In the middle of October 2022, Zentralklinik Bad Berka became the very first hospital to be awarded the “Thüringer Siegel für gesunde Arbeit” (Thuringian Seal for Healthy Working) in silver. Companies certified with this seal are committed to the health of their employees and have been able to demonstrate that their employees enjoy healthy working condi- tions based on defined quality criteria. The “Netzwerk Gesunde Arbeit in Thüringen” (Network of Healthy Work in Thuringia), which is based at the Ernst-Abbe-Hochschule – University of Applied Sciences in Jena, issues the certificate to promote healthy workplaces. That in- cludes sustainable organisational structures, a healthy management structure and offerings to safeguard and promote the health and working capacity of staff. Ensuring fair compensation through in-house collective agreements and special benefits Fair remuneration has an influence on employee satisfaction. Our employees benefit from in-house collective agreements we have negotiated for our hospitals with the social partners ver.di and Marburger Bund. Compared with the other collective wage agree- ments in the healthcare system our employees enjoy, for example, high night-shift premiums and differential surcharges exempt of tax and social insurance contributions. With all these measures we want to express our high degree of appreciation for our employees, who were already performing great work before the pandemic. In addition to a “Job Ticket” for local public transport, we also offer a leasing model for financing a “Job Bike”. Promoting health with the Employee Assistant Programme | After deciding to introduce the Employee Assistance Programme (EAP) in 2021 and establishing it at the hospital sites of Frankfurt (Oder), Giessen and Marburg, the advisory concept was expanded to the Bad Neustadt and Bad Berka sites in April 2022. This measure is also part of our aim to promote the health of our employees. Under the EAP, employees of RHÖN-KLINIKUM AG can take advantage of con- sultations with the trained and knowledgeable staff of Fürstenberg Institut whenever they find themselves in difficult personal situations. Employees are thus provided with assistance in finding their way out RHÖN-KLINIKUM AG | Annual Report 2022 41

CORPORATE RESPONSIBILITY | Corporate Social Responsibility Report | Employees RHÖN-KLINIKUM IT Service GmbH also further expanded its training offering. In addition to the existing offerings for vocational training as an “IT specialist” (Fachinformatiker) and “digitalisation manage- ment specialist” (Kaufmann für Digitalisierungsmanagement), it has been accredited as a training partner since June and in collaboration with the Baden-Wuerttemberg Cooperative State University (DHBW) has offered for the first time since October the dual study pro- gramme “Business Information Systems, Degree Course in E-Health” (Wirtschaftsinformatik, Studiengang E-Health). In financial year 2022, RHÖN-KLINIKUM AG renewed its membership with the association promoting young researchers, “Initiative Junge Forscherinnen und Forscher e. V. (IJF)”, by an additional three years until the end of 2024. Three years ago the joint MINT (Math, Infor- matics, Natural sciences, Technology) education project of the IJF, RHÖN-KLINIKUM AG and the technical and vocational school Staatliche Fachoberschule und Berufsoberschule Bad Neustadt a. d. Saale (FOS- BOS) was launched for the first time. Together the partners wish to revive the employment market in the region and encourage young people to pursue careers in science, technology and information technology. The project days of the IJF at FOSBOS combine theory and practice. RHÖN-KLINIKUM AG supports the training cooperative and organises excursions to the Campus Bad Neustadt providing insights into state-of-the-art medical technology and digital appli- cations for patient care. During the reporting period, three FOSBOS excursions to the Campus were carried out in July 2022. Attractive employer We embrace diversity During the reporting period, people from some 70 nations worked for our Group. Irrespective of their age, gender identity, qualifications or what their interests may be, they work side by side on a daily basis and perform outstanding work. The basis for that is respectful and fair dealings with one another. For us diversity is a self-evident part of our day-to-day hospital activities. We are fully committed to diversity and stand against discrimination or harassment in any form. We maintain the principle of equal opportunities by filling positions exclusively on the basis of qualifications. Almost 30 per cent of executives at the three management levels below the Board of Management are wom- en. We also make sure that our teams are made up of both young and experienced employees. APPRENTICES, TRAINING YEAR 1–3 2022 (2021) Headcount 29 (41) 961 (1,011) 1,764 (1,721) 774 (669) Apprentices, nursing professions (nurses, etc.) Apprentices, commercial professions Apprentices, other professions We invest in tomorrow’s young talent In 2021, the vocational training for the professions of geriatric, health- care and paediatric nurse was combined into vocational training for the profession of general nurse practitioner (Pflegefachkraft). Thanks to our early preparations we were able to satisfy all requirements for the new general nurse practitioner training programme in accordance with the new Care Professions Reform Act (Pflegeberufereformgesetz, PflBRefG) and to fully ensure the training programme. In particular, we succeeded in finding suitable partners for all training fields. In 2022, we also continued the collaborative training agreements that began in 2020 and entered into new partnerships. We are bringing about rising attendance and digitalisation at our now hospital-affiliated schools. As a healthcare Group, we operate several schools to train qualified staff ourselves. These include schools for nursing care, physiotherapy, ergotherapy, speech therapy, dieti- cian services, and for medical assistance professions in the areas of functional diagnosis (MTAF), laboratory (MTLA), radiology (MTRA) and medical documentation (MDA). We also provide vocational training in the business, gastronomy and IT fields. RHÖN-KLINIKUM AG | Annual Report 2022 43

CORPORATE RESPONSIBILITY | Corporate Social Responsibility Report | Compliance COMPLIANCE The compliance standards at RHÖN-KLINIKUM AG promote the legally compliant conduct of our employees. This is sustained and supported by our Group – both internally within our Company and in the relationship with our external stakeholders. | Trust between clinical staff and patients is the basis of our day- to-day work. We understand this in light of the principle that “We treat all people in the same way we also would like to be treated ourselves.”. This principle applies without exception to all our employees. Compliance rules promote fair dealings in internal and external relationships | Our compliance management system provides the framework for legally compliant behaviour, fair dealings and responsible corporate governance. The compliance management system is continuously enhanced. Our Group-wide principles of conduct – communicat- ed to all employees in November 2022 – define the requirements describing the relationship with our patients, customers, suppliers, shareholders and the general public as well as the conduct of our employees amongst one another. Trust between clinical staff and patients is the basis of our day- to-day work. | The highest level of responsibility for compliance is held by the Chairman of the Board of Management who reports to the Audit Committee of the Supervisory Board. A Central Compliance depart- ment for establishing the compliance framework is set up at the Group level. | The restructuring and collaboration between RHÖN-KLINIKUM AG and the Asklepios Group in the area of compliance presented in 2021 Annual Report was introduced and implemented in 2022. | The Central Compliance department is supported locally by com- pliance officers. They report to this central department and act as local contacts. Specific efforts were made to step up the collaboration be- tween both levels in the course of the year. The compliance officers at the subsidiaries were kept regularly informed and received further training in specific subjects through in-person and online courses. | To ensure an ongoing exchange between the Risk Management, Internal Auditing and Compliance departments, a Compliance Com- mittee meets each quarter and deals amongst other things with com- pliance cases and their risk assessment. Response to compliance reports | Employees of RHÖN-KLINIKUM AG can submit compliance reports using various reporting channels. In addition to written reports sent by post and e-mail, reports may also be made by telephone. | In addition to the senior executives, the employees of the Central Compliance department as well as the compliance officers at the in- dividual hospital sites and in other subsidiaries of RHÖN-KLINIKUM AG in particular also act as contact persons when compliance reports are made. If compliance reports are not addressed to the Central Compli- ance department directly, they are as a rule immediately forwarded by the addressee of a report to the Central Compliance department. The Central Compliance department organises the review of the facts of the respective compliance report. RHÖN-KLINIKUM AG | Annual Report 2022 45

CORPORATE RESPONSIBILITY | Corporate Social Responsibility Report | Environmental protection ENVIRONMENTAL PROTECTION We bear a responsibility. And this responsibility goes well beyond the well-being of our patients and employees. Of course, we also assume responsibility for our environment. This is reflected, for example, in the conscientious management of our energy and water resources. In addition, ensuring the lowest possible waste and emissions levels is the guiding principle of our Company for protecting the environment. Environmental management | Ensuring the well-being of our patients and taking good care of the environment are a top priority for RHÖN-KLINIKUM AG. Our main focus and concern here is to reduce CO₂, waste volumes and water consumption without making compromises when it comes to ensuring the safety and comfort in the care we provide to our patients. | Based on its decentralised structure, environmental manage- ment at RHÖN-KLINIKUM AG is established at two levels: firstly in the technical control departments of the hospitals and secondly at the Group Construction and Technology division. Overall responsibility lies with the Board of Management. The respective technical control department is responsible for the hospital’s safe operation: it monitors all technical and medical-technical equipment and systems but also construction projects, and takes on the task of energy controlling as well as refurbishment and optimisation planning. Where required, it is assisted in all measures by the Construction and Technology divi- sion of the Group: it advises the hospitals of RHÖN -KLINIKUM AG on questions of energy management and provides assistance with major investment measures at the hospital sites, above all refurbishment and expansion measures. | Since the end of 2016, we have pooled procurement of energy Group-wide in the company RHÖN Energie für Gesundheit GmbH. This enables us to obtain more attractive purchasing prices for elec- tricity and gas and gives us a centralised overview of the energy con- sumed and monthly controlling. Since 2021, RHÖN-KLINIKUM Energie für Gesundheit GmbH has placed these services with AKTIF GmbH. This external service provider has been tasked with allocating and charging the energy purchased to the facilities of RHÖN-KLINKUM AG, as well as with informing the management of any changes in legis- lation in a timely manner and advising it accordingly. AKTIF GmbH also acts for the Asklepios Group as an expert in the energy sector and is also slated to provide assistance in transforming the area of energy management. After the expiry of the existing contracts for gas and electricity purchases, these energy requirements are to be covered jointly on the market. Currently, the fixed-price contracts will continue until the end of 2023. Our main focus in this regard will be on ensuring the most efficient electricity consumption possible in our operative business, with our primary goal being to minimise unnecessary energy consumption independent of the energy mix. Nonetheless, in future tenders we will endeavour to further optimise the ecological and economic targets and to increase even further the current share of renewable energy. | The first energy audit to DIN EN 162471-1 was conducted in 2016. In 2020, we had an energy audit conducted and successfully concluded once again. The next statutorily prescribed audit is due to take place in 2024. | In all matters of environmental management, we also maintain a continuous and close dialogue with the relevant departments of the Asklepios Group. Lowering energy consumption and emissions | Modern hospital operations need a lot of energy. We use a wide variety of technical equipment and systems that are important for the treatment and care of our patients. Our patients and employ- ees rely on rooms being kept at the right temperature. And the in- creasing pace of digitalisation and expansion of equipment-based medical care will also result in an increasing demand for energy. At RHÖN-KLINIKUM AG, emissions are produced primarily in the form of carbon dioxide (CO₂) from heat generation or from electricity pur- chases. Through modernisation measures, energy efficiency improve- ments and the use of renewable energies, we are looking to curb the increase in such emissions. RHÖN-KLINIKUM AG | Annual Report 2022 47

CORPORATE RESPONSIBILITY | Corporate Social Responsibility Report | Environmental protection Implementing energy optimisation measures | The potential for saving energy features very prominently in all refurbishment measures we perform on our buildings. During the reporting period we identified and adopted some new approaches in this regard. | An inspection of roof surfaces with a view to installing photo- voltaic systems has been performed at all sites. In a further step, we are currently preparing an analysis of the economic profitability of mounting and using such systems on our roof surfaces. The profit- ability analysis has now been completed for the Bad Neustadt site and is to be successively continued for other sites. | Compared with the previous year 2021, we succeeded during the 2022 reporting year in realising significant savings of 547,216 megawatt hours (kWh) at the Bad Neustadt site thanks, amongst other things, to the targeted use of intelligent building control systems. This was achieved through the optimisation of ventilation, heating and cooling systems – outside highly sensitive areas. The additional installation of twilight sensors, motion detectors, adjustment of timers in the building control systems as well as the installation of additional LED lamps have also helped bring about a further reduction. In addi- tion, an existing hospital building will be used as an administration building in future following an overhaul of its energy facilities. | Moreover, the Bad Berka site will see its four existing cogene- ration plants replaced, existing heating boilers adapted to the new requirements and the central cooling unit brought in line with the new operating environment in several construction stages by the end of 2024. In future, CO₂ emissions will be significantly reduced and energy costs reduced annually by roughly 340,000 euros once the project has been completed. | At the Frankfurt (Oder) site, the replacement of the lighting sys- tem was continued during the reporting year as part of the refur- bishment project, and the instrumentation and control equipment was further modernised. | In Marburg, a metering concept differentiating between third-party consumers has been installed since January 2022. For this purpose, a total of 130 metering points were installed to measure the consumption of external service providers such as bakeries or pharmacies. This represents an important step towards a full energy management system. Suitable spaces at this site were also equipped with motion detectors to reduce energy consumption. | During the 2022 reporting year, the “Green Hospital” working group was established at UKGM. This employee working group repre- senting various professional groups from different hospitals develops ideas for integrating environmental protection into the day-to-day work of hospitals. Depending on the area of focus, representatives/ senior executives from different business and clinical areas are invited to the working group’s meetings. One of the first successes achieved by the working group was to improve the collection of recyclable materials and glass in the central surgery wing of the University Hos- pital of Marburg. | With the aim of raising awareness and exchanging information, we initiated the lecture series “Climate crisis and health” in 2021 with the participation of the University Hospital of Marburg, which we also continued in 2022. These publicly accessible lectures deal extensively with the impact of climate change on human health. The lecture series is addressed to citizens and patients; the opening event was moderated by Dr Eckart von Hirschhausen. | In all new construction and refurbishment measures, we provide for redundancy and availability of the technical facilities to make sure we are ready for any failure of the external energy supply grid. Two emergency power generators per hospital ensure self-sufficiency in electricity for several days. With oil-operated backup boilers, we moreover ensure a supply with sufficient heat and, where applicable, steam. We are thus able to ensure safe patient care in the event of protracted external supply failures. Reducing climate-harmful anaesthetic gases | All anaesthetic gases are direct and potent greenhouse gases. They accelerate global warming when they enter the atmosphere through the exhaust air. The process of filtering anaesthetic gases from exhaust air is not only expensive but also energy-intensive and not very efficient. The department of anaesthesiology and operative intensive-care medicine at the University of Giessen and the depart- ment of anaesthesia and intensive care at the University of Marburg succeeded in completely eliminating the use of desflurane, a partic- ularly harmful anaesthetic gas, after gradually reducing its use. Des- flurane has now been replaced by other volatile anaesthetic gases. This not only lowers costs but is also good for the environment. For the most part it has been possible to switch anaesthesia to other re- gimes, such as total intravenous anaesthesia (TIVA) and regional block anaesthetics. The same thing holds true for laughing gas, which is also used in anaesthesia techniques. Here, too, consumption has been further reduced. In Marburg, laughing gas is no longer used and in Giessen only in special paediatric anaesthesia indications. In Giessen, there are also efforts to eliminate anaesthetic gas scavenging with the aim of saving energy during those hours when no anaesthesia procedures are performed. RHÖN-KLINIKUM AG | Annual Report 2022 49

CORPORATE RESPONSIBILITY | Corporate Social Responsibility Report | Environmental protection | During the reporting period, the amount of category A-B waste produced was 4,299 t (previous year: 4,636 t). Compared with the previous year, the volume of category A-B waste thus fell by 7.3 per cent. Category C-E waste decreased to 132 t (previous year: 155 t). The lower waste volumes are attributable to successful measures such as training courses and instructions on waste avoidance and recycling. Reducing water consumption, ensuring water purity | (Drinking) water is a valuable resource that is not always avail- able in all parts of the world. That is why we are also engaged in targeted efforts to lower water consumption in our day-to-day clinical activities. | Thus, we have implemented a number of measures in recent years enabling us to conserve water to a noticeable extent. All toilets are equipped with water-saving buttons for minimum flushing vol- umes. The sink fixtures are set to predetermined limits on the amount and temperature of the water running through them. | For a healthcare group like RHÖN-KLINIKUM AG, it is absolutely es- sential to be able to offer high-quality drinking water. That is why we drew up our own “Water Use Policy” years ago. Strict compliance with the requirements of this Policy is to ensure the high quality of drinking water from the point of delivery from the public water mains to the final point of use. We also conduct regular water quality inspections through microbiological tests that exceed the legal requirements. | During the 2022 reporting year, the measures we took, despite higher recooling effects as a result of the hotter summer, reduced water consumption by roughly 1.9 per cent to 634,451 m3 (previous year: 646,628 m3).3 | For environmental reasons it is also very important to us to keep contaminant levels in our waste water as low as possible. Waste water contaminants result from separation of contrast agents or medica- tions. Waste water containing grease from the preparation of foods as a rule is passed through grease separators and only then discharged to the public sewerage system. In our kitchens, we also dispensed with the use of cleaning and disinfection products containing chlo- rine. In 2022, the amount of waste water at all sites was roughly 596,545 m3 (previous year: 617,747 m3).4 We are developing innovative climate concepts of the future | RHÖN-KLINIKUM AG is aware of the general significance and urgency of climate change mitigation and is assuming its responsi- bility. We act on this by developing viable climate change mitigation concepts for the future. We are currently gradually developing a com- prehensive Group-wide climate and sustainability strategy for the coming years. We will report on the scope and goals of this strategy after it has been completed. New system of indicators to enable comparability of Groups and consistent presentation | In financial year 2022, RHÖN-KLINIKUM AG reported on its environ- mental KPIs outside the main text in a tabular presentation form for the first time. The KPIs meet a Group-wide standard and create com- parability of the subgroups of the Asklepios Group as well as consis- tent presentation. | ENVIRONMENTAL PROTECTION INDICATORS (KPIs) Indicator Total energy consumption (electricity) Third-party purchase (electricity) Electricity consumption (ex CHPs + PV) Natural gas consumption (ex CHPs + PV) District heating Self-generated energy Electric energy produced by CHPs Heat produced by CHPs Number of CHPs Photovoltaic Mix of energies (main electricity supplier) Renewable energy sources Nuclear power Coal/lignite and natural gas Other fossil fuels Waste, total weight Water consumption Direct emissions (Scope 1) Indirect emissions from energy provided (Scope 2) Unit GWh GWh GWh GWh GWh GWh number Value 114.7 76.2 85.4 42.5 40.3 51.8 4 GWh 0.000352 per cent per cent per cent per cent t m3 t CO₂ t CO₂ 24.2 15.5 58.7 1.6 5,132 634,451 45,544 38,333 3/4 The figures of the previous year were adjusted as a result of a new calculation method. RHÖN-KLINIKUM AG | Annual Report 2022 51

CORPORATE RESPONSIBILITY | Corporate Social Responsibility Report | Supplier management With an interdisciplinary team the requirements of the German Supply Chain Act are being implemented in accordance with the statutory requirements centrally within RHÖN-KLINIKUM AG in collaboration with the Group parent company Asklepios. Standardisation of products ensures their availability For some time we have been trying to standardise and harmonise the products we purchase. The primary goal is to use only those prod- ucts that have proven themselves from a medical standpoint and are characterised by outstanding quality and excellent long-term results. This is followed by the cost aspect, since many manufacturers give rebates on large volume purchases. As the frank discussion amongst the materials management heads and in the medical expert panels of RHÖN-KLINIKUM AG has revealed, such standardisation does not lend itself to all products. The purpose of the Act on Corporate Due Diligence Obligations in Supply Chains (Lieferkettensorgfaltspflichtengesetz, LkSG) is to improve the situation of human rights internationally by defining requirements and standards of responsible management of supply chains for certain companies. With an interdisciplinary team the re- quirements of the Act are being implemented in accordance with the statutory requirements centrally within RHÖN-KLINIKUM AG in collab- oration with the Group parent company Asklepios. Even before the new Act was introduced, we were acting in accordance with Kant’s imperative to “act only in accordance with that maxim through which you can at the same time will that it should become a universal law”. However, standardisation has proven advantageous in the follow- ing medical areas: – endoprosthetics (hips, knees, kyphoplasty, etc.) – cardiology (pacemakers, defibrillators, heart valves, stents, etc.) – anaesthetics (tubing, syringes and sensors, etc.) – laboratory medicine (urine diagnostics, blood gas analysis, etc.) – nursing (urine measurement systems, surgery drapes, suctioning, dressing materials, infusion solutions, sanitary products, etc.), – hygiene products (water filters, disinfectants, etc.) In the non-medical area, we are pursuing for example the standardi- sation of office items or paper as well as the harmonisation of service providers in the technical area, and are also switching over our goods management systems to one uniform system for all hospital sites. Supplier management indicators (KPIs) | In the 2022 Annual Report, the following KPIs are published at the Group level for the first time. The KPIs published on the basis of a Group-wide standard will help create comparability of the subgroups of the Asklepios Group as well as consistent presentation. | SUPPLIER MANAGEMENT INDICATORS (KPIS) Indicator Procurement volume Total number of suppliers Unit € m number Value 446.6 3,543 RHÖN-KLINIKUM AG | Annual Report 2022 53

Group Management Report 1 | Basic characteristics of the RHÖN-KLINIKUM Group 1.1 Overview 1.2 Future of the Group 1.3 Objectives and strategies 1.4 Controlling system 1.5 Quality 1.6 Medical research and its transfer into practice 1.7 Compliance 1.8 Corporate Governance 1.9 Declaration on Corporate Governance 2 | Economic report 2.1 Macroeconomic conditions 2.2 Sector-specific conditions 2.3 Business performance 3 | Forecast report 3.1 Strategic objectives 3.2 Economic and legal environment 3.3 Forecast 4 | Opportunities and risk report 4.1 Risk report 4.2 Report on opportunities 5 | Reporting pursuant to section 315 (4) of the German Commercial Code (Handelsgesetzbuch, HGB) 57 57 57 58 59 60 60 60 61 63 64 64 64 65 70 70 70 70 71 71 76 78 RHÖN-KLINIKUM AG | Annual Report 2022 55

GROUP MANAGEMENT REPORT | Basic characteristics of the RHÖN-KLINIKUM Group 1 | BASIC CHARACTERISTICS OF THE RHÖN-KLINIKUM GROUP 1.1 Overview Within the Group of RHÖN-KLINIKUM AG, mainly cross-sector (i.e. inpatient, semi-inpatient and outpatient) healthcare services are provided. With few exceptions, the Group has a single-tier structure. With the exception of Campus Bad Neustadt, the individual hospital companies are organised in the form of legally independent corpor- ations having their registered office at the respective facility sites and are managed as direct subsidiaries of RHÖN-KLINIKUM AG (ultimate Group parent company). The ultimate Group parent company has its registered office in Bad Neustadt a. d. Saale, Federal Republic of Germany. With eight hospitals and 5,445 beds/places at a total of five sites in four federal states, we are one of the largest hospital operators in Germany. A total of 855,333 patients (previous year: 845,642) were treated in our facilities in financial year 2022. With revenues of € 1,446.1 million (previous year: € 1,402.0 million), we generated EBITDA amounting to € 105.6 million (previous year: € 101.2 million) despite the considerable impacts of inflation, the energy crisis, supply challenges as well as the subsiding but still continuing effects of the COVID-19 pandemic during the course of the year. At the balance sheet date, the Group employed 18,140 persons (31 December 2021: 18,227). Future of the Group 1.2 At RHÖN-KLINIKUM AG financial year 2022 was marked by the response to the COVID-19 pandemic and efforts to cope with the impacts of the war in Ukraine. We are now also facing new challenges from taking in and providing medical care to refugees and injured people, overcom- ing the energy and procurement crisis as well as coping with rising inflation. At the end of February 2023, an agreement was reached in the negotiations with the Federal State of Hesse on the implementation of the Letter of Intent signed in January 2022 relating to the grant of investment funding as well as enhancing what is referred to as separate accounting. Over the next ten years, the Federal State of Hesse and Universitätsklinikum Gießen und Marburg (UKGM) want to invest nearly € 850 million at the Giessen and Marburg sites to safeguard optimum healthcare delivery to people in the region, the quality of research and teaching as well as job security. Our most pressing tasks in the Company include improving provision of services at the hospitals and a return to normal after the COVID-19 pandemic, expanding outpatient care structures and offerings, digital- isation as well as measures to address the shortages in qualified staff. Attractiveness as employer With 18,140 employees, RHÖN-KLINIKUM AG is one of the largest healthcare groups in Germany. For years we have been committed to excellent medical care, competence and know-how as well as maintaining a close relationship based on a human approach. For RHÖN-KLINIKUM AG, diversity is a self-evident part of our day-to-day hospital activities. We are fully committed to diversity and stand firmly against discrimination or harassment in any form. As an established hospital operator, we enjoy an excellent reputation as an employer and training provider. We offer good opportunities for personal advancement and continuously invest in the training of new staff members as well as the qualification of employees. As seen from our health management approach, we give top priority to look- ing after our employees’ needs, particularly given the considerable challenges they had to face during the COVID-19 pandemic. We take care of our employees – also with offerings helping them to balance their family and career – and look after their health. And we realise that keeping a work-life balance is also key when it comes to maintaining stable mental and physical health. That is why we see it as our duty to create the environment in which our em ployees can succeed in harmonising their professional and personal life. Medical and nursing excellence RHÖN-KLINIKUM AG enjoys a high standing in the medical commu- nity. Our physicians are among Germany’s top medical professionals and our hospitals are recognised for their high standards of treatment quality. Many of them hold multiple certifications. As attractive large intermediate- and maximum-care facilities with ac- cess to university medicine, our hospitals have a unique selling point. The strong interdisciplinary cooperation enabling specific therapies for our patients based on state-of-the-art diagnostics ensures a holistic provision of medical, nursing and therapeutic care to patients. Our goals are to continuously improve the quality of medical care, further increase patient safety and satisfaction as well as improve pa- tient communications and patient services. We also plan to broaden our existing scope of outpatient care and cooperation with the aim of avoiding unnecessary inpatient hospital stays for our patients. Corporate code In this regard, the ethical principle underlying everything RHÖN-KLINIKUM AG does is “Don’t do to others what you would not like done to yourself, and don’t leave off doing anything that you would like done to yourself.” It is characterised by expertise and knowledge, closeness and humanity, responsibility and integrity. RHÖN-KLINIKUM AG | Annual Report 2022 57

GROUP MANAGEMENT REPORT | Basic characteristics of the RHÖN-KLINIKUM Group concepts of healthcare delivery to ensure we can continue providing excellent medical care. Under the common structure with Asklepios, we have created the ideal basis for meeting the challenges of our sector head-on and taking advantage of the Group’s economies of scale for each individual facility and hospital in the best possible way. In Germany, we have a very good healthcare system with highly quali- fied and committed employees. To make sure this stays that way in future, this heavily regulated system must be funded in line with the principle of dual financing. That means that the operating costs are borne by the healthcare funds and the investment costs of the hospitals by the federal states regardless of their ownership (public or private) and their care level or category. It is therefore vital for the federal states to once again better meet their statutory responsibility to assume the investment costs and to ensure the future viability of hospitals in Germany. For Universitätsklinikum Gießen und Marburg, an agreement was reached at the end of marathon negotiations by the Federal State of Hesse and the managers of our Group, the universities and the university hospital on the latter’s entitlement to investment funding. This agreement was signed in February 2023. After RHÖN-KLINIKUM AG had already invested over € 750 million of its own funds in the university hospital in the past, the next ten years will see further amounts of almost € 850 million being invested in healthcare delivery as well as research and teaching. We are firmly convinced that Universitätsklinikum Gießen und Marburg can look ahead to good prospects for the long term. We continue to pursue our objective of taking on new challenges and meeting them through appropriate investments. In addition to advances in medicine, we will press ahead even further with digital- isation and drive the change on the healthcare delivery landscape by promoting specialisation whilst at the same time expanding out- patient medicine through comprehensive and targeted investments. Here, the sound foundation in healthcare delivery for research and teaching will be further strengthened, and providing patients with cutting-edge medical care will continue to be safeguarded. We see some of our most pressing tasks in the Company in the follow- ing further areas of action: strengthening nursing and medical care, ensuring that hospitals concentrate on their core activities, further optimising processes as well as pooling know-how, for example at the (in some cases newly established) service companies providing in-house services. Our objectives continue to be ambitious and will present RHÖN-KLINIKUM AG and our employees with a wide range of chal- lenges. People from over 70 nations work for RHÖN. Each day they work together in a team and do outstanding work. Here, we pay considerable attention to retaining and recruiting qualified staff, particularly also given the general shortage of qualified staff in the medical and nursing fields. We continue to offer our employees good opportunities for personal advancement and are continuously invest- ing in initial and ongoing training as well as in attractive offerings for our staff. Sustainability and environmental protection are fundamental issues of our times to which RHÖN-KLINIKUM AG has committed itself. Mod- ern hospital operations need a lot of energy, whether for the state- of-the-art building technology, the wide array of medical devices or increasing digitalisation. We have taken on the task of ensuring energy-optimised operations as we invest in sustainable technol- ogies. The goal is to reduce CO2 emissions, waste volumes and water consumption – without compromising when it comes to ensuring the safety and comfort in the care we provide to our patients. Not a few hospitals will have to close down due to the huge cost pressures and in the wake of the planned hospital reform. Increas- ingly, they are also being faced with massive cost hikes for energy, medical goods or services which they cannot refinance. Many differ- ent structural changes are needed to preserve the efficiency of the healthcare system in Germany. Our ongoing aim is to pursue new paths to uphold the standard of offering the best medical care to our patients. In this way we can bet- ter respond to the changes and increasing requirements as compared with the market as a whole thanks to the merger with Asklepios and our large sites with highly specialised centres. Here, our RHÖN Cam- pus approach for cross-sector and future-oriented healthcare delivery in rural areas will make an increasingly significant conceptual con- tribution towards creating the care delivery structures of the future. We will also vigorously and undauntedly continue to pursue the ne ces sary task of helping to reshape the healthcare system and implementing our corporate goals. 1.4 Controlling system The RHÖN-KLINIKUM Group is directed and controlled by the Board of Management of RHÖN-KLINIKUM AG. The Group is controlled giving due regard to medical, strategic and financial targets. The target system defines key figures of relevance for control such as revenues and EBITDA, as well as key figures for quality and growth in medical service volumes and consolidated profit. Key ratios are RHÖN-KLINIKUM AG | Annual Report 2022 59

GROUP MANAGEMENT REPORT | Basic characteristics of the RHÖN-KLINIKUM Group by our Group – both internally within our Company and in the rela- tionship with our external stakeholders. Trust between clinical staff and patients is the basis of our day-to-day work. We understand this in light of the principle that “We treat all people in the same way we also would like to be treated ourselves”. This principle applies without exception to all our employees. Our compliance management system provides the framework for legally compliant behaviour, fair dealings and responsible corporate governance. The compliance management system is continuously enhanced. Our Group-wide principles of conduct – communicat- ed to all employees in November 2022 – define the requirements describing the relationship with our patients, customers, suppliers, shareholders and the general public as well as the conduct of our employees amongst one another. For further information, reference is made to the separate non- financial report in accordance with section 315c in conjunction with sections 289c to 289e of the HGB in the Annual Report published on our website. 1.8 Corporate Governance Subscribed capital The subscribed capital of RHÖN-KLINIKUM AG stated in the consolidat- ed financial statements is completely made up of 66,962,470 ordinary voting bearer shares (non-par shares) each having a nominal share in the registered share capital of € 2.50. Restrictions on voting rights or the transfer of shares – even if these may result from agreements of shareholders – do not exist or are not known to us. None of our shares is issued with special rights that confer on its holder special powers of control. Employees who hold shares exercise their voting rights freely. Shareholders may exercise their voting rights themselves at the Annual General Meeting or through proxies appointed for this purpose. Based on the threshold events notified to us, the following picture pursuant to section 33 f. of the German Securities Trading Act (Wertpapierhandelsgesetz, WpHG) in terms of shareholder structure emerges as at the relevant key date of 31 December 2022: Person subject to notification requirement Published on Held directly % Attributed % Date that interest exceeds/falls below the threshold Interest exceeding/ falling below threshold in the case of Voting rights held % Notification pursuant to section 33 et seq. WpHG attribution pursuant to WpHG/ additional information Dr Bernard große Broermann/ Eugen Münch; AMR Holding GmbH 23 July 2020/ 24 July 2020 0.0005 93.37 93.38 22 July 2020 > 75% Attributed (section 34 WpHG): AMR Holding GmbH RHÖN-KLINIKUM AG | Annual Report 2022 61

GROUP MANAGEMENT REPORT | Basic characteristics of the RHÖN-KLINIKUM Group Company with effect from 31 October 2022. At its meeting on 18 October 2022, the Supervisory Board appointed Prof. Dr Tobias Kaltenbach to the Board of Management as chairman of the Board of Management with effect from 1 November 2022. Prof. Dr Bernd Griewing (Chief Medical Officer, CMO) resigned from the Board of Management with effect from 31 October 2022 and on 1 November 2022 changed his function from CMO to the position of a generally authorised representative. The responsibilities within the Board of Management were adjusted accordingly. As at 31 December 2022, the Board of Management of RHÖN-KLINIKUM AG is composed of three members: Prof. Dr Tobias Kaltenbach (CEO), Dr Stefan Stranz (CFO) and Dr Gunther K. Weiß (COO). For information on remuneration of the Board of Management and of the Supervisory Board, reference is made to the Remuneration Report published on our website. Shareholdings of members of corporate bodies As at 31 December 2022, the members of the Supervisory Board and the Board of Management and their related parties together held, pursuant to Article 19 of the Market Abuse Regulation (MAR), 0.0% (previous year: 0.0%) of the Company’s registered share capital, of which the Supervisory Board and its related parties account for 0.0% (previous year: 0.0%) of the shares in issue. As in the previous year, the members of the Board of Management and their related parties do not hold any interests in the registered share capital. We continue to disclose all transactions of members of the Board of Management and the Supervisory Board which are subject to notifi- cation pursuant to Article 19 of the MAR. Other contracts containing a change-of-control clause The White Paper Plus (Zukunftspapier Plus) signed at the end of Feb- ruary 2023 between the Federal State of Hesse, RHÖN -KLINIKUM AG, Asklepios Kliniken GmbH & Co. KGaA, Universitätsklinikum Gießen und Marburg GmbH (UKGM) as well as their universities with their faculties of medicine relating to the granting of investment funds for UKGM provides, as of 1 January 2023, for a retransfer of shares to the Federal State of Hesse under certain circumstances in the event of a change of control. A change of control exists if 50% of the shares in RHÖN-KLINIKUM AG or more than 50% of the shares in Asklepios Kliniken GmbH & Co. KGaA or its personally liable shareholder is ac- quired by another natural or legal person. Various contracts relating to financial instruments exist in which the lenders may demand immediate repayment in the event of a change of control. In this regard a change of control is defined as the takeover of more than 50% of the interests in RHÖN-KLINIKUM AG. For the former anchor shareholders B. Braun Melsungen AG/Asklepios Kliniken GmbH & Co. KGaA/Mr. Münch (HCM SE) and Ms. Münch, exceptions did and do exist in the promissory note loan agreement from financial year 2018 and the registered bond from financial year 2019. According to the contract documentation, no change of control exists if one or more of the former anchor shareholders acquire(s) more than 50%, but no more than 70.1% maximum (promissory note loan agreement 2018) and 70.3% maximum (registered bond 2019), respectively, of the voting shares in RHÖN-KLINIKUM AG within the group of anchor shareholders. Declaration on Corporate Governance 1.9 The Declaration on Corporate Governance, in addition to the Declar- ation of Compliance of the Board of Management and the Supervisory Board pursuant to section 161 of the AktG, also contains information on corporate governance practices, the work approach of the Board of Management and the Supervisory Board as well as the committees established by them, reporting on equal participation of men and women in management positions and the diversity concept. For further details please visit our website www.rhoen-klinikum-ag.com where the Declaration on Corporate Governance is made accessible to the public under the section “Corporate Governance”. RHÖN-KLINIKUM AG | Annual Report 2022 63

GROUP MANAGEMENT REPORT | Economic report The legislator is thus seeking to avoid unnecessary overnight hos- pital stays and reduce the workload on nursing staff. Moreover, a uniform sector remuneration (regardless of whether the treatment is performed on an inpatient or outpatient basis) will be introduced for certain treatments to further press ahead with outpatient isation. By 31 March 2023, healthcare funds, hospitals and the National Associations of Statutory Health Insurance Physicians (kassenärztliche Bundesvereinigungen) are to jointly define suitable services from the catalogue of outpatient operations as well as an appropriate remuner- ation. Moreover, the Act contains provisions on determining staffing levels, on time limits for budget negotiations, on funding training for nursing assistance and nursing support staff, on extending the hygiene funding programme in the form of an infectiology funding programme by three years, on teleconsulting services as well as on telematics infrastructure and the pharmaceuticals area. The ongoing war in Ukraine has disrupted supply chains and as a result has led to a general rise in prices. In the view of the Board of Management of RHÖN-KLINIKUM AG, the discordance between the statutory reimbursement mechanisms on the one hand and the in- flationary price trend on the other is having a considerable impact on the German healthcare industry. After weathering the adverse effects of the pandemic, hospitals now face the impacts of inflation and in particular higher energy prices. To support hospitals in the context of these energy price hikes, the German legislator has launched a relief programme. For the period of October 2022 to April 2024, section 26f of the KHG provides for lump-sum relief payments for indirect increases in costs as well as refunds to individual hospitals for direct cost increases resulting from the purchase of grid-bound natural gas, grid-bound district heat and grid-bound electricity. 2.3 Business performance 2.3.1 Overall statement on economic position Financial year 2022 was once again dominated by the efforts to cope with the pandemic, excessive staff workloads and shortages of quali- fied staff as well as exploding material and procurement costs. We are now also facing new challenges from taking in and providing medical care to refugees and injured people from war zones as well as the sharp increases in purchasing prices. Despite these huge tasks, we report a rise in EBITDA by € 4.4 million to € 105.6 million as well as a rise in EBIT by € 5.6 million to € 36.1 million in financial year 2022, thanks to a total rise in patient numbers by 1.1% as well as a € 44.1 million increase in revenues. Consolidated profit decreased by € 3.3 million to € 26.9 million. 2.3.2 Trend in service volumes As at 31 December 2021 Change in capacities As at 31 December 2022 Hospitals Beds 8 – 8 5,420 25 5,445 Since 31 December 2021, adjustments in hospital plans and renewals of care delivery contracts resulted in minor changes in our inpatient as well as semi-inpatient and day clinic capacities: Approved beds/ places Change 31 Dec. 2022 31 Dec. 2021 absolute in % Inpatient capacities Acute hospitals Rehabilitation hospitals and other inpatient facilities Semi-inpatient and day-clinical capacities Total 4,634 4,619 602 602 5,236 5,221 209 199 5,445 5,420 15 0 15 10 25 0.3 0.0 0.3 5.0 0.5 As at 31 December 2022, we operate nine medical care centres with a total of 61.75 specialist practices: Medical care centres Specialist practices 9 – – 9 58.75 1.00 2.00 61.75 As at 31 December 2021 Opened/acquired MVZ Bad Berka MVZ Frankfurt (Oder) As at 31 December 2022 RHÖN-KLINIKUM AG | Annual Report 2022 65

GROUP MANAGEMENT REPORT | Economic report As a result of higher purchasing prices, materials and consumables used witnessed an increase, disproportionate to the rise in revenues, by € 16.2 million or 3.8% in financial year 2022 compared with the same period of the previous year. The cost-of-materials ratio climbed from 30.7% to 30.9%. The interest of RHÖN-KLINIKUM AG shareholders in profit for financial year 2022 declined by € 3.2 million to € 25.1 million (previous year: € 28.3 million) compared with the previous year. This translates into earnings per share of € 0.38 (previous year: € 0.42) in accordance with IAS 33. As the number of employees declined, the employee benefits ex- pense rose compared with the same period of the previous year attributable to general wage increases. As in the previous year, the personnel expense ratio was 65.7%. Other expenses saw an increase from € 147.3 million by € 16.9 million to € 164.2 million. The other expense ratio rose from 10.5% to 11.4%. The increase is essentially attributable to higher payments for training facilities, maintenance and servicing requirements, higher personnel and continued training costs, as well as insurance expenses. The depreciation and impairment item declined compared with the same period of the previous year by € 1.2 million or 1.7% to € 69.5 million. The depreciation/amortisation ratio fell slightly from 5.0% to 4.8%. The negative finance result improved in financial year 2022 by € 0.6 million to € 2.5 million, which was essentially thanks to a gen- erally favourable trend in interest rates. At an unchanged rate of taxation, the income tax expense item rose by € 9.5 million compared with the same period last year. Here, it has to be borne in mind that the figure of € 5.1 million from the previous year was helped by the reversal of provisions formed in the context of risk provisioning for income tax risks relating to the sale of subsidiar- ies. Moreover, the effect of a higher tax assessment basis in financial year 2022 was recognised with effect on the income statement. The total result (sum of consolidated profit and other earnings) for financial year 2022 stands at € 27.3 million (previous year: € 34.9 mil- lion). In this connection, gains from changes in fair value through other comprehensive income (FVOCI) in the amount of € 0.3 million (previous year: € 4.7 million) as well as gains from the revaluation of defined benefit pension plans amounting to € 0.1 million (previous year: € 0.0 million) had to be recognised directly at equity. 2.3.4 Net assets and financial position in € million Assets Non-current assets Current assets Liabilities 31 Dec. 2022 31 Dec. 2021 in % 1,016.3 688.6 59.6 40.4 1,054.5 611.1 in % 63.3 36.7 1,704.9 100.0 1,665.6 100.0 Shareholders’ equity 1,251.4 73.4 1,224.8 Long-term loan capital Short-term loan capital 162.4 291.1 9.5 17.1 167.5 273.3 73.5 10.1 16.4 1,704.9 100.0 1,665.6 100.0 Consolidated profit declined slightly by € 3.3 million to € 26.9 million (previous year: € 30.2 million). Non-controlling interests in profit decreased compared with the same period last year by € 0.1 million to € 1.8 million (previous year: € 1.9 million). Compared with the balance sheet date of 31 December 2021, the balance sheet total rose by € 39.3 million or 2.4% to € 1,704.9 million (previous year: € 1,665.6 million). With revenues of € 1.4 billion, we met our forecast for revenues for 2022 made in the 2021 Group Management Report for € 1.4 billion with our actual figure within a range or plus or minus 5%. In the ad hoc notification of 30 January 2023, EBITDA forecast in the 2021 Group Management Report was adjusted. We also met the fore- cast for EBITDA made in the aforementioned ad hoc notification for financial year 2022 of between € 103 million and € 109 million with the actual figure of € 105.6 million. At 73.4%, the equity capital ratio is still at a high level. As at 31 Decem- ber 2022, equity stands at € 1,251.4 million (previous year: € 1,224.8 mil- lion). The increase in equity capital compared with the reporting date of 31 December 2021 by € 26.6 million results from consolidated profit of financial year 2022 (€ 26.9 million), gains from the change in the fair value through other comprehensive income (FVOCI) (€ 0.2 million), and gains from the revaluation of defined benefit pension plans (€ 0.1 mil- lion), on the one hand, and the equity-decreasing effects from dividend payments to non-controlling interests (€ 0.6 million), on the other. RHÖN-KLINIKUM AG | Annual Report 2022 67

GROUP MANAGEMENT REPORT | Economic report During financial year 2022, we invested a total of € 56.0 million (previous year: € 75.8 million) in intangible assets, in property, plant and equipment as well as in investment property. Of this total, € 19.1 million (previous year: € 16.7 million) relates to capital expenditure funded under hospital financing law, with the grants being reflected as a deduction from acquisition cost. In the consolidated financial statements we report net investments of € 36.9 million (previous year: € 59.1 million). Current capital expen- diture accounted for € 36.6 million (previous year: € 58.7 million) and assets and specialist practices acquired on takeovers for € 0.3 million (previous year: € 0.4 million) of total net investments during the year under review. An analysis of investments financed from Company funds by site in financial year 2022 is given below: The White Paper Plus (Zukunftspapier Plus) signed at the end of Feb- ruary 2023 between the Federal State of Hesse, RHÖN -KLINIKUM AG, Asklepios Kliniken GmbH & Co. KGaA, Universitätsklinikum Gießen und Marburg GmbH (UKGM) as well as the universities with their faculties of medicine relating to the granting of investment funds for UKGM provides for further investment obligations to be financed from own funds over the next ten years in the amount of € 259.0 million as of 1 January 2023. As at the balance sheet date, we do not have any investment obliga- tions under Company acquisition agreements entered into. 2.3.6 Employees On 31 December 2022, the Group employed 18,140 persons (31 De- cember 2021: 18,227): Number As at 31 December 2021 Change in employees at hospital companies Change in employees at medical care centre companies Change in employees at service companies As at 31 December 2022 18,227 –238 –9 160 18,140 Doctors accounted for 15.4% (previous year: 15.3%) of the total head- count on the reporting date, while nursing and medical-technical staff accounted for 55.1% (previous year: 54.8%). On average over the year, we recorded a slight decline of 0.7% in full-time staff. As in the previous year, the share of women remains at around 72%. in € million Giessen, Marburg Bad Neustadt a. d. Saale Bad Berka Frankfurt (Oder) Total 18.3 7.9 6.1 4.6 36.9 The agreement with the Federal State of Hesse in connection with the financing of the services to be rendered for research and teaching at the Group’s university hospitals from 2017 provides for investment commitments in the amount of € 100.0 million until 2021. Already as at the balance sheet date of 31 December 2021, these investment obligations were fully met. There are also further obligations relating to building refurbishments and extension measures at the Giessen and Marburg sites which were initially due to be completed by 31 De- cember 2024. With the White Paper (Zukunftspapier) signed at the end of February 2023, investment projects under the agreement from 2017 were modified and the time limits for meeting the investment obligations adjusted. The time limits for meeting these investment obligations are now in the time frame between 31 December 2024 and 31 December 2028. RHÖN-KLINIKUM AG | Annual Report 2022 69

GROUP MANAGEMENT REPORT | Opportunities and risk report 4 | OPPORTUNITIES AND RISK REPORT A decisive element of a value-oriented and sustainable corporate governance is a company’s wholehearted embracement of risk and opportunity management. The capacity to adequately weigh up op- portunities and risks is a crucial factor of entrepreneurial success, and that decisively depends on the quality of the decisions made by a company’s management. Within the Group of RHÖN-KLINIKUM AG, we therefore see managing risks and opportunities as well as con- trolling these effectively and on a sustainable basis as a core entre- preneurial task firmly enshrined in our management culture. Our risk management objectives are based on our values-oriented corporate strategy of protecting the Company’s resources from risks of substan- tial losses, identifying new opportunities as well as safeguarding the interests of all stakeholders giving due regard to social and environ- mental factors. Our corporate activity is inseparably bound up with risks and oppor- tunities. As a service provider in the healthcare sector, we operate in an extremely complex risk environment. The challenge for us is to ensure reasonable management of these risks – since it is only companies that recognise their material risks in time and take steps to systematically counter the same that are also able at the same time to identify the opportunities arising and to exploit them in an entrepreneurially responsible manner. This involves continuously weighing up opportunities against the risks. As a provider of health- care services, we always regard the risk posed to the life and health of our patients and our employees as the greatest risk. We give ut- most priority to measures that avoid even the smallest errors in the medical and nursing area. Further factors such as the regulatory and legislative environment, continually mounting cost, competitive and consolidation pressures within the sector, the rising expectations for the quality of inpatient healthcare delivery and the expectations of patients present opportunities but also involve risks. 4.1 Risk report 4.1.1 Risk management system The Board of Management of RHÖN-KLINIKUM AG has implemented a Group-wide risk management system to detect imminent risks early on and to specifically counter them in a systematic process. In this regard, the risk management system covers the totality of all provi- sions ensuring a structured response to risks and rewards throughout the Group, and acts as an active instrument of control to support the achievement of the corporate objectives. Our risk management system forms an integral part of the internal controlling system fully meeting the statutory requirements for early detection of risks posing a threat to the Company’s existence as well as the requirements of section 91 (2) and (3) of the AktG. The centrally managed risk man- agement function has the task of continually further developing and optimising the system. The basis for our risk management system is the Group risk guideline containing both the risk strategy and objectives, the definition of the term ‘risk’ and the principles of risk management, as well as describing the requirements for the risk management process uniformly binding on the Group as a whole including the related duties and respon- sibilities. The actual risk management process is documented in a risk management software program. Thanks to an open risk culture, regular training and feedback sessions, we ensure acceptance of risk management within the Company. The Internal Auditing department is entrusted by the Board of Management with the process-related re- view of matters as required in specific cases. In this connection, it also monitors the operability and correct application of the corresponding requirements in sub-divisions or companies of RHÖN-KLINIKUM AG. Definition By risks we understand events and potential developments within and outside RHÖN-KLINIKUM AG that might adversely impact the achievement of the Company’s stated objectives, future performance of tasks as well as the quality and reputation of RHÖN-KLINIKUM AG and its subsidiaries. By analogy to the definition of risk, we understand opportunities as events and potential developments that may have a positive impact. Risk management process We understand risk management as an ongoing process that is divided into the phases of: – risk identification, – risk analysis and evaluation, – risk control and management, – risk communication, – risk monitoring. These processes are to ensure that potential risks are made manage- able and opportunities are identified. All risks meeting the definitions of the Group risk guideline are to be reported. At the same time, our risk management function relates not only to financial risks but also all manner of risks within the Company. We regard the risk to the life and health of our patients potentially resulting from a medical intervention as the greatest risk. With us, identifying risks and recognising opportunities are integrated into our standard business procedures, since it is only when we are aware of risks and opportunities that we can manage and control them. Risk identification encompasses the systematic and struc- tured documentation of all relevant risks in the Company, with risk classes always being assessed in terms of their strategic and operative impacts as well as in view of the risks of reporting and potential com- pliance risks. Given constantly changing circumstances and require- ments, risk identification is an ongoing task, and is performed on RHÖN-KLINIKUM AG | Annual Report 2022 71

GROUP MANAGEMENT REPORT | Opportunities and risk report General environment and industry risks We are affected only indirectly by developments in the German econ- o my since healthcare spending is influenced by contribution volumes of the insured and thus by the job market situation. However, the war against Ukraine, the energy crisis, inflation, disrupted supply chains, global warming as a result of climate change, the COVID-19 pandemic and other geopolitical and macroeconomic challenges are things that always affect the health of people and the care provided to them. At the beginning of 2023, the Robert Koch Institute (RKI) downgraded its assessment of the threat posed by Corona infections to “moderate”. The inpatient treatment of COVID-19 patients has become part of regular clinical operations. In addition to providing the best possible medical care for our patients, we continue to focus our attention on coping with the economic impact of the pandemic. In the macroeco- nomic environment, we see financial risks arising from the general trend in price levels as well as higher material costs, energy costs and wage adjustments. It is not possible to quantify such risks at this time. Furthermore, the industry environment is characterised by height- ened influences from healthcare policy regulation. Even if Germany has made it through the pandemic relatively unscathed, it has never- theless exposed significant vulnerabilities in our healthcare system, especially also the poor leverage of digital technologies in cross-sec- tor healthcare delivery. In many areas the German healthcare system lacks a sustainable and resilient basis and must be much better pre- pared for crises such as pandemics and the effects of climate change. Political reforms are indispensable. Together with our strong partners in the Asklepios Group as well as our networks, we can bring in our experience here. For this reason we maintain a regular dialogue with local, state and federal politicians. Particularly the continued devel- opment of nursing regulation (PpUGV) and the changes brought in by the Nursing Staff Strengthening Act (PpSG) create new layers of bureaucracy, and instead of making the medical and nursing profes- sions more attractive will continue to put a drag on earnings. A further industry-specific risk is the underfinancing of the German healthcare system with government grants and, in relation to that, a violation of the principle of dual financing inherent in the relevant legislation. The Hospital Future Act (Krankenhauszukunftsgesetz, KHZG) is a first step in the right direction. Basically, it provides for investment funding for hospital modernisation and greater funding of emergency capacities and digital structures. But the investments contemplated in this piece of legislation fall well short of what is needed to remove the investment backlog in the German health- care system. To implement successfully the dynamic potential and complexity of digitalisation, further policy framework conditions have to be created where patients must be the focus of interest. For us, digitalisation is one of the prerequisites for innovations and better healthcare delivery. We continue to assume that the demand for medical services, especially cutting-edge medical services, will return to the level of the pre-pandemic era. At the same time it is possible that remuneration (which under the DRGs system is exclusively performance-oriented) cannot be supplemented or ad equately adjusted in the short term. Parallel to that, there will continue to be an increasing shift of what were once inpatient services to the outpatient care sector. To successfully counter this shift in service volumes, inpatient overcapacities in hospitals would have to be reduced throughout Germany and outpatient capacities ramped up. But this will require outpatient facilities to be established specifically for that purpose as part of the network of inpatient hospitals and financed through hybrid DRGs. For that reason we are gearing our efforts towards ensuring that we can achieve the continuous economic growth in service volumes needed in our core business with our already implemented campus approach, also in future. With the currently tabled reform plans of the Government Commis- sion (hospital reform) that are to be implemented by the end of the year into an acceptable law, these and other far-reaching changes in the hospital landscape might be in the offing. Under these plans, hospital care levels are to be defined uniformly throughout Germany in three levels; each level will be assigned so-called minimum struc- tural requirements and the care levels will be remuneration relevant (revenue-independent flat-fee financing (Vorhaltefinanzierung)). The general thrust and direction of these recommendations is right. There is a need for discussion in terms of their details and specific imple- mentation. We hold a good position given the size of our facilities, and will adequately respond to the impending changes. As far as possible, the above developments have already been taken into account in our targets. Looking to the future, we will counter them through suitable activities and measures. Further regulatory and industry risks relating to us are classified as low. The new pro- visions of the legislator may lead to further risks for the hospitals of RHÖN-KLINIKUM AG. Since we pursue a comprehensive risk management approach, the identification and any assessment of non-financial risks may also arise from the analysis of financially assessed risks. In this context, com- pliance risks of our Group are particularly important when it comes to assessing sector-specific risks. These include the mandatory ob- servance of statutory provisions (e.g. data protection regulations). RHÖN-KLINIKUM AG | Annual Report 2022 73

GROUP MANAGEMENT REPORT | Opportunities and risk report In addition to the typical clinical risk fields in the area of patient safety (hygiene, nursing and medical care), potential risks are also seen, as in the previous years, in infrastructure (such as fire risks) and in technical equipment. According to the new General Data Protection Regulation (GDPR), companies dealing with personal health data are subject to a particularly high degree of accountability and must be able to furnish proof of the “integrity and confidentiality” of data processing. We are well prepared for this level of IT security (cyber risks) and should be able to reasonably withstand any targeted attacks. Overall, we rate the risk position in this area as low, particularly given the existing measures in place. For risks in the clinical area that cannot be fully averted, the Group has adequate insurance coverage which is regularly reviewed and updated. The operating risks relate in particular to operative risks of the Group subsidiaries of RHÖN-KLINIKUM AG. Human resource risks To achieve sustained success as a diversified healthcare group with leading expertise, we need the required number of committed and highly qualified employees and executive staff. Hospitals on average have personnel cost ratios of between 50% and 70%, making them particularly dependent on qualified staff and developments in wages. As for the entire industry as well, rising demand for specialists and the related shortage of qualified staff are issues of key importance for us, with regional differences being apparent depending on the specific facilities. For us, too, finding highly qualified and motivated staff to meet the wide-ranging and complex requirements of the healthcare industry is a challenge. We meet these requirements with numerous measures at our sites tailored to local challenges. As a mod- ern employer we offer not only modern remuneration structures, an attractive work environment, in-house kindergartens at the hospitals, provision of affordable apartments and assistance in searching for apartments, but also a wide range of career options and benefits. Recruiting and retaining qualified staff at our Company is of key im- portance to us. For example, we run state-recognised schools for nursing and non-medical professions, and through our academic teaching hospitals are committed to training medical students to the highest standards. Furthermore, thanks to our cooperation with other universities, we make contact at an early stage with qualified grad- uates so that we can recruit the necessary young talent for our staff. Given the further establishment and expansion of structured recruit- ing and qualification concepts for doctors, nursing and healthcare professionals as well as for our executive talent, however, we currently see opportunities to efficiently counteract the current shortage of personnel and currently still classify HR risks throughout the Group as relatively low. Personnel risks relate in particular to operative risks of the Group subsidiaries of RHÖN-KLINIKUM AG. Procurement risks In the area of materials management, RHÖN-KLINIKUM AG is working together closely with Asklepios Großhandelsgesellschaft mbH under a cooperation agreement aimed at strengthening care security at the sites with adequate conditions. For materials procurement in the areas of medical facilities, equip- ment as well as medical supplies and energy supply, we rely on ex- ternal providers. These business ties can give rise to risks that are triggered, for example, by supply and quality problems. Already during the pandemic, supply shortages and product unavailability increased and were further exacerbated with disproportionate price increases by the geopolitical situation with the war against Ukraine. The problems associated with that have now become a reality in day- to-day business operations and are taken into account in planning. The fixed price contracts for the purchase of gas and electricity will continue until the end of 2023. Higher procurement costs are already taken into account in the multi-year forecast and will be adjusted after the follow-on agreement. Thanks to the cooperation agreement with Asklepios and measures already taken, we continue to assess the risk in this area as low overall. Procurement risks relate in particular to operative risks of the Group subsidiaries of RHÖN-KLINIKUM AG. Financial risks RHÖN-KLINIKUM AG is characterised by a high and sound capital base, a sustainable internal financing strength and a strong liquid- ity position in the triple-digit million euro range. Our three-pronged RHÖN-KLINIKUM AG | Annual Report 2022 75

GROUP MANAGEMENT REPORT | Opportunities and risk report We see a tremendous need for healthcare policy reform. The health- care system in Germany, like other areas of society and the econ- omy, is continuously being confronted with structural changes. This structural transformation offers huge potential for innovation and opportunities to shape the healthcare system of the future and is bringing about lasting change in the healthcare system. With the planned hospital reform, existing structures are being changed and a fresh look is being taken at existing processes and solutions. With our campus approach, the consistent implementation of outpatient- isation as well as the establishment of new medical services, we will seize the opportunities afforded by these developments and realise them in the best interests of our patients. As one of the leading providers of healthcare in Germany, we as RHÖN-KLINIKUM AG play a trailblazing role in the healthcare industry with our campus and digitalisation strategy. Our campus approach, which integrates outpatient and inpatient care and takes a holistic view of the patient, is a viable care model of the future. We are thus setting standards for excellent medical care – not just in rural areas. Since the integration of outpatient and inpatient care calls for a high level of digitalisation, we will further forge ahead with digitalisation to further reduce the workload on our staff with a view to standardising structures and clinical processes and thus ultimately further improv- ing the quality of healthcare in the interests of the patients treated. We have already made great strides in digitalisation so far: perform- ing paperless bedside work with a tablet so that patient data are available everywhere, the use of the web software solution Samedi, the project Derma Online, the pilot project E-Health-Programm Minddistrict, etc. – to name just a few. One focus is on introducing telematics infrastructure, one of the strongest and most future-orient- ed trends in healthcare with the digital networking and integration of all persons involved in the treatment process: community-based practitioners, rehab facilities and other providers further down the chain of care delivery. Already before the pandemic, declining inpatient case numbers as well as the trend towards outpatientisation were a sign of the times. In future, up to 25% of acute inpatient treatments are to be treated on an outpatient basis. To seize the opportunities of outpatientisation, digital solutions funded by the German Hospital Future Act (KHZG) are helping support decisions on the right form of care delivery. For that reason, it will be even more important for decision-making pro- cesses ensuring the best-possible care to be made already before patients are admitted to the hospital based on a digital integration of emergency dispatch centres and emergency services. In addition to the advance in digitalisation, the conceptual and con- structional modernisation of our sites continues to be a major issue. Our extensive investments at almost all sites of the Group will result in positive impacts on medical care for patients. Overall, we see ourselves very well positioned thanks to the partner- ship with Asklepios. Also in future, we will continue to be amongst the major hospital operators in Germany operating as an efficient, homogenous Group with a consistent orientation and focus on cutting-edge medicine geared towards maximum care, as well as the further strengthening of treatment excellence and patient care through our focus on digitalisation and network medical care. To this end we avail ourselves of all opportunities presented to us and counteract the potential risks with a practised and functioning risk management approach. For the impacts of the new investment agreements between the Federal State of Hesse and Universitätsklinikum Gießen und Marburg (UKGM), we refer to the statements made in the previous sections of this Group Management Report. RHÖN-KLINIKUM AG | Annual Report 2022 77

Consolidated financial statements Consolidated balance sheet Consolidated income statement Consolidated statement of comprehensive income Statement of changes in equity Statement of cash flows Notes Contents of the consolidated financial statements General information Accounting policies Critical estimates and assessments in accounting and valuation Company acquisitions Notes to the consolidated income statement Notes to the consolidated balance sheet Statement of cash flows Shareholdings Other disclosures Corporate bodies of RHÖN-KLINIKUM AG Responsibility statement Independent auditor’s report 80 82 83 84 85 86 88 88 103 106 107 112 130 132 134 146 149 150 RHÖN-KLINIKUM AG | Annual Report 2022 RHÖN-KLINIKUM AG | Annual Report 2022 79

CONSOLIDATED FINANCIAL STATEMENTS | Consolidated balance sheet Notes 31 Dec. 2022 31 Dec. 2021 6.12 6.13 6.14 6.17 6.13 6.16 6.19 6.15 6.17 6.18 167,406 574,168 482,304 –76 167,406 574,168 456,821 –76 1,223,802 1,198,319 27,631 26,460 1,251,433 1,224,779 141,675 519 20,234 162,428 7,966 69,986 11,205 33,964 11,576 156,386 291,083 148,564 1,365 17,576 167,505 997 72,492 14,577 32,200 12,068 140,979 273,313 1,704,944 1,665,597 EQUITY AND LIABILITIES in € ’000 Shareholders’ equity Issued share capital Capital reserve Other reserves Treasury shares Equity attributable to shareholders of RHÖN-KLINIKUM AG Non-controlling interests in equity Non-current liabilities Financial liabilities Provisions for post-employment benefits Other financial liabilities Current liabilities Financial liabilities Trade payables Current income tax liabilities Other provisions Other financial liabilities Other liabilities RHÖN-KLINIKUM AG | Annual Report 2022 81

CONSOLIDATED FINANCIAL STATEMENTS | Consolidated statement of comprehensive income Consolidated statement of comprehensive income 1 JANUARY TO 31 DECEMBER 2022 in € ’000 Consolidated profit of which non-controlling interests shareholders of RHÖN-KLINIKUM AG Changes in fair value through other comprehensive income (FVOCI) Income taxes Other comprehensive income (changes in fair value through other comprehensive income) not subsequently reclassified to income statement Revaluation of defined benefit pension plans Income taxes Other comprehensive income (revaluation of pension plans) not subsequently reclassified to income statement 6.5 6.3 6.14 6.3 Other comprehensive income1 of which non-controlling interests shareholders of RHÖN-KLINIKUM AG Total comprehensive income of which non-controlling interests shareholders of RHÖN-KLINIKUM AG 1 Sum of value changes recognised directly at equity. Notes 2022 2021 26,940 30,227 1,796 25,144 303 –47 256 98 –15 83 339 – 339 1,932 28,295 5,551 –878 4,673 27 –5 22 4,695 – 4,695 27,279 34,922 1,796 25,483 1,932 32,990 RHÖN-KLINIKUM AG | Annual Report 2022 83

CONSOLIDATED FINANCIAL STATEMENTS | Statement of cash flows Statement of cash flows in € million Earnings before taxes Finance result (net) Depreciation/amortisation and impairment and gains/losses on disposal of assets Change in net current assets Change in inventories Change in trade receivables Change in other financial assets and other assets Change in trade payables Change in other net liabilities/other non-cash transactions Change in provisions Income taxes paid Interest paid Cash generated from operating activities Investments in property, plant and equipment and in intangible assets Government grants received to finance investments in property, plant and equipment and in intangible assets Change in investments in fixed term deposits Investments in financial assets Acquisition of subsidiaries, net of cash acquired Sale proceeds from disposal of assets Interest received Cash used in investing activities Principal payments for leases Payments to non-controlling interests in equity Cash used in financing activities Change in cash and cash equivalents Cash and cash equivalents at 1 January Cash and cash equivalents as at 31 December RHÖN-KLINIKUM AG | Annual Report 2022 Notes 2022 2021 5.9 5.5 6.6 6.7 6.8 et seq. 6.16 6.15/6.17 et seq. 6.14 et seq. 5.10 6.1 et seq. 6.5/6.8 6.5 4 9.3 6.12 6.11 33.6 2.5 69.6 105.7 –0.2 –15.7 –57.7 2.6 19.5 1.0 –9.3 –4.6 41.3 –58.2 19.1 –53.0 4.6 –0.3 0.4 1.2 –86.2 –3.5 –0.6 –4.1 –49.0 126.3 77.3 27.4 3.1 70.2 100.7 2.1 –18.9 8.3 –2.4 7.0 0.1 4.4 –3.8 97.5 –77.8 16.7 – 0.1 –0.4 2.7 0.4 –58.3 –3.5 –0.4 –3.9 35.3 91.0 126.3 85

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Contents 107 107 107 108 108 108 108 109 109 109 110 111 111 112 112 114 115 116 116 116 117 117 117 118 119 119 119 120 121 122 6.15 Other provisions 123 6.16 Trade payables 124 6.17 Other financial liabilities 124 6.18 Other liabilities 125 6.19 Current income tax liabilities 125 6.20 Derivative financial instruments 125 6.21 Additional disclosures regarding financial instruments 126 6.21.1 Carrying amounts, recognised figures and fair values according to measurement categories 126 6.21.2 Net gains or losses by measurement category 129 130 6.21.3 Financial liabilities (maturity analysis) 7 | Statement of cash flows 8 | Shareholdings 8.1 Companies included in the consolidated annual report 8.2 Other companies according to section 313 (2) No. 2 et seq. HGB 9 | Other disclosures 9.1 Average annual number of employees 9.2 Other financial obligations 9.3 Leases within the Group 9.4 Related parties 9.5 Total payments of Supervisory Board, the Obligations of lessees Investment property 9.3.1 9.3.2 Board of Management and the Advisory Board 9.6 Declaration of Compliance with the German Corporate Governance Code 9.7 Disclosure of the fees recognised as expenses (including reimbursement of outlays and excluding VAT) for the statutory auditors 9.8 Events after the reporting date 10 | Corporate bodies of RHÖN-KLINIKUM AG 130 132 132 133 134 134 134 135 135 135 136 140 145 145 145 146 87 Notes to the consolidated income statement 5.1 Revenues 5.2 Other income 5.3 Materials and consumables used 5.4 Employee benefits expense 5.5 Depreciation and impairment 5.6 Other expenses 5.7 Result from impairment on financial assets 5.8 Research costs 5.9 Finance result – net 5.10 Income taxes 5.11 Non-controlling interests in profit 5.12 Earnings per share Notes to the consolidated balance sheet 6.1 Goodwill and other intangible assets 6.2 Property, plant and equipment 6.3 Deferred tax assets 6.4 Financial investments accounted for using the equity method 6.4.1 Investments accounted for using the equity method 6.4.2 Joint ventures Other financial assets (non-current) 6.5 6.6 Inventories 6.7 Trade receivables 6.8 Other financial assets (current) 6.9 Other assets (current) 6.10 Current income tax assets 6.11 Cash and cash equivalents 6.12 Equity 6.13 Financial liabilities 6.14 Provisions for post-employment benefits 5 | 6 | RHÖN-KLINIKUM AG | Annual Report 2022

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Accounting policies The Standards and Interpretations adopted by the European Union are explained below: Amendments to IFRS 3: “Business Combinations” The amendments to IFRS 3 “Business Combinations” relate to a refer- ence within the Standard to the conceptual framework of IFRS (2018). Furthermore, the Standard was supplemented by the requirement for purchasers to apply the provisions of IAS 37 or IFRIC 21 instead of the conceptual framework when identifying obligations assumed that fall under the scope of application of IAS 37 or IFRIC 21. By way of exception, this does not apply to contingent liabilities, to which the exemption from IFRS 3.23 will continue to apply. Moreover, the Standard was supplemented by an explicit recognition prohibition for acquired contingent assets. The amendments adopted into European law on 28 June 2021 are to be applied to financial years be ginning on or after 1 January 2022, and are of no practical relevance for RHÖN-KLINIKUM AG. Amendments to IFRS 16: “Property, Plant and Equipment” The amendments to IAS 16 “Property, Plant and Equipment” clarify that proceeds an entity has received from selling items produced while bringing an asset into the location and condition necessary for it to be capable of operating in the manner intended and the costs associated therewith are to be recognised in profit or loss. It is not permissible to recognise such amounts in determining acquisition cost. The amendments adopted into European law on 28 June 2021 are to be applied to financial years beginning on or after 1 January 2022 and are of no practical relevance for RHÖN-KLINIKUM AG. Amendments to IAS 37: “Provisions, Contingent Liabilities and Contingent Assets” By the amendments to IAS 37 “Provisions, Contingent Liabilities and Contingent Assets” it is clarified that all costs of fulfilling a con- tract directly attributable to the contract are to be included in the determination of whether the contract is onerous as defined in IAS 37. Costs directly attributable to the contract, in addition to the costs additionally incurring to an entity as a result of the contract (“ incremental cost”) such as direct wage and material costs, also include other costs directly attributable to the fulfilling of the contract such as a proportionate depreciation charges of an item of property, plant and equipment used in fulfilling the contract. The amendments adopted into European law on 28 June 2021 are to be applied to financial years beginning on or after 1 January 2022 and are currently of no practical relevance for RHÖN-KLINIKUM AG. Amendments: “Annual Improvements to IFRS, 2018–2020 Cycle” On 14 May 2020 the IASB, as part of its annual improvements, pub- lished minor amendments to Standards IFRS 1, IFRS 9, IFRS 16 and IAS 41. The amendments to IFRS 1 relate to the treatment of cumula- tive currency differences in the initial adoption of IFRS by a subsidiary. In IFRS 9 it was clarified which fees are to be included if a “10% test” is applied in assessing whether to derecognise a financial liability. Moreover, in IFRS 16 an example was removed from the Appendix to the Standard to provide for greater clarity. In IAS 41 an adjustment was made to ensure consistency with the provisions in IFRS 13 when determining fair values. The amendments adopted into European law on 28 June 2021 are to be applied to financial years beginning on or after 1 January 2022 and are of no practical relevance for, or have no material impact on, the net assets and results of operations of RHÖN-KLINIKUM AG. RHÖN-KLINIKUM AG | Annual Report 2022 89

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Accounting policies The Standards and Interpretations already adopted by the European Union are explained below: Amendments to IFRS 17: “Insurance Contracts” The amendments to IFRS 17 “Insurance Contracts” were adopted into European law on 19 November 2021. They provide that for contracts with participation features, as are common in Germany and a number of other EU countries, entities are given the option of being exempted from applying IFRS 17.22. IFRS 17.22 provides that in the subsequent measurement only those contracts concluded no more than one year apart may be measured together. When utilising the exemption, entities may now measure contracts in the subsequent measure- ment together, regardless of the time interval between conclusion of the contracts, and prior to applying the imparity principle may net profitable and loss-making contracts concluded at very different times. The amendments are to be applied to financial years begin- ning on or after 1 January 2023 and are of no practical relevance for RHÖN-KLINIKUM AG. Amendments to IFRS 17: “Insurance Contracts” – initial application of IAS 17 and IFRS 9 – Comparative Information With the amendments to Standard IFRS 17 “Insurance Contracts”, first- time adopters of this Standard can present financial assets during the comparative period as if the classification and measurement rules in IFRS 9 had been applied to such financial assets (classification overlay). For this the entity is to use a classification of the financial assets which the entity expects at the date of initial application on the basis of reasonable and reliable information. Up to the initial application of the provisions in IFRS 17 and IFRS 9 existing up to such date, accounting mismatches could arise if comparative information for financial assets was not retroactively adjusted to the provisions of IFRS 9. The amend- ments to Standard IFRS 17 may also be applied by those accounting entities having implemented IFRS 9 already before the transition to IFRS 17. These entities can apply the classification overlay to financial assets derecognised during the comparative period if they use the provisions set out in IFRS 17 for the reassessment of the classification of financial assets in the transition to IFRS 17. Entities which apply the classification overlay to financial assets are not required to also apply the impairment provisions of IFRS 9 to such financial assets. The amendments adopted into European law on 8 September 2022 are to be applied to financial years beginning on or after 1 January 2023 and are of no practical relevance for RHÖN-KLINIKUM AG. Amendments to IAS 1: “Presentation of Financial Statements” – Scope of Accounting Policies in an IFRS appendix The amendments to IAS 1 “Presentation of Financial Statements” clarify that in future disclosures are to be made only for material and no longer for significant accounting policies. In this regard, accounting policies relating to immaterial transactions or events are in turn to be regarded as immaterial and thus not subject to disclosure. Here, immateriality is to be assessed not only quantitatively but also quali- tatively. Accounting policies relating to material transactions or events may be material but do not necessarily have to be. The Standard con- tains information and explanations on when disclosures on account- ing policies are to be regarded as material. The basic principles to be considered for determining when an accounting policy is deemed material were also included in the IFRS Practice Statement 2 “ Making Materiality Judgements” and explained in the form of a decision tree. The amendments, which were adopted into European law on 2 March 2022, are to be applied to financial years commencing on or after 1 January 2023 and have no material impact on the net assets, financial position and results of operations of RHÖN-KLINIKUM AG. Amendments to IAS 8: “Accounting Policies” – Definition of an Accounting Estimate The amendments to IAS 8 “Accounting Policies, Changes in Account- ing Estimates and Errors” clarify the distinction between accounting policies and accounting estimates and redefine the term “account- ing estimates”. Under the new definition, “accounting estimates” are monetary amounts in financial statements that are subject to measurement uncertainty. The term “accounting estimate” thus represents a value which, in the case of existing measurement uncertainties, is determined using measurement techniques and input factors to achieve the objective of the accounting policy to be applied. The amendments, which were adopted into European law on 2 March 2022, are to be applied to financial years commencing on or after 1 January 2023 and have no material impact on the net assets, financial position and results of operations of RHÖN-KLINIKUM AG. Amendments to IAS 12: “Income Taxes” – Recognition Prohibition for Deferred Tax on Initial Recognition of an Asset or Liability The amendments to IAS 12 “Income Taxes” qualify the initial recog- nition exception (IRE). Up to now, it prohibited an entity from recog- nising deferred tax on initial recognition of an asset or liability in a transaction which is not a business combination and affects neither accounting nor taxable profit. Under the revised IRE, the question of the recognition or non-recognition of deferred tax assets or liabilities RHÖN-KLINIKUM AG | Annual Report 2022 91

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Accounting policies difference is recognised directly in the consolidated income state- ment. Group-internal transactions and balances as well as unrealised gains and losses from transactions between Group companies are eliminated. To the extent necessary, the accounting policies of sub- sidiaries are adjusted to ensure application of uniform accounting principles within the Group. 2.3.1 Transactions with non-controlling interests Transactions with non-controlling interests are treated like transac- tions with equity investors. Any difference arising on acquisition of a non-controlling interest between the consideration paid and the relevant share in the carrying amount of the subsidiary’s net assets is recognised in equity. Positive or negative effects arising on disposal of non-controlling interests are likewise recognised in equity. This applies only to the extent the disposal does not give rise to any loss of control. 2.3.2 Associated companies and joint ventures Associated companies are those companies over which the Group has a substantial influence. A substantial influence is refutably presumed if the share of voting rights is between 20.0% and 50.0%. Investments in associated companies and jointly controlled entities (joint ventures) are accounted for using the equity method and initially recognised at cost. The Group’s interest in associated companies and jointly controlled entities includes the goodwill arising on acquisition (less accumulated impairment losses). The Group’s interest in the profits and losses of associated companies or joint ventures is recognised in the income statement as of the date of acquisition and the cumulative changes are offset against the carrying amount of the investment. Changes in equity without effect in profit or loss are not to be considered. If the Group’s share in the loss of an associate or joint venture is equal to or greater than the Group’s share in this company including other unsecured receiv- ables, no further losses are recognised unless the Group has entered into an obligation for the associate or jointly controlled entity or has made payments for it. Unrealised intercompany profits or losses from transactions between Group companies and associated companies or joint ventures are eliminated on a pro rata basis if the underlying circumstances are material. In an impairment test, the carrying amount of a company accounted for using the equity method is compared with its recoverable amount. If the carrying amount exceeds the recoverable amount, an impair- ment equal to the difference must be recognised. If the reasons for a previously recognised impairment have ceased to exist, the impair- ment is reversed through the income statement. The financial statements of investments accounted for using the equity method are prepared using uniform accounting principles within the Group. Associated companies whose individual or overall impact on the net assets and results of operations is not material are not accounted for using the equity method. They are included in the consolidated financial statements at fair value. Immaterial equity interests are measured at fair value through profit or loss. 2.3.3 Sale of subsidiaries and associated companies If the Group loses either control or material influence over a company, the remaining interest is remeasured at fair value and the resulting difference recognised as profit or loss. Fair value is the fair value cal- culated upon the initial recognition of an associate, joint venture or financial asset. Moreover, all amounts stated in other income are recognised with reference to such company in the same way as would be required if the related assets and liabilities had been sold by the parent company directly. That means that a profit or loss previously recognised under other income is transferred to the income state- ment. If it cannot be transferred to the income statement, it remains in equity (e.g. actuarial profits or losses from pensions). RHÖN-KLINIKUM AG | Annual Report 2022 93

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Accounting policies 2.4.2 Computer software Purchased computer software licences are recognised at cost plus the cost of bringing them to their working condition. These costs are amortised over the estimated useful life (three to seven years, straight-line method), and are shown under “depreciation/amorti- sation and impairment” in the income statement. Costs relating to the development of websites or maintenance of computer software are expensed as incurred if the conditions for capitalisation are not satisfied pursuant to IAS 38. 2.4.3 Other intangible assets Other intangible assets are stated at historic cost and – to the extent depletable – amortised over their respective useful lives (three to five years) using the straight-line method, and are shown under “depreci- ation/amortisation and impairment” in the income statement. 2.4.4 Research and development expenses Research costs are recognised as current expenditure in accordance with IAS 38. Development costs are capitalised if all the criteria of IAS 38 are satisfied. There are no development costs that meet the criteria for capitalisation. 2.5 Property, plant and equipment Land and buildings are reported under “Property, plant and equip- ment” and mainly comprise hospital buildings. In the same way as the other items of property, plant and equipment, they are measured at cost less any depreciation. Cost includes the expenditure directly attributable to the acquisition or construction of an asset as well as any overheads attributable to construction. Subsequent costs are recognised as part of the cost of the asset or – where applicable – as a separate asset only if it is probable that future economic benefits associated with the asset will accrue to the Group and if the cost of the asset can be measured reliably. All other repair and maintenance work is recognised as expenditure in the income statement in the financial year in which it is incurred. Property, plant and equipment are tested for impairment if events or changed circumstances suggest that an impairment may have occurred. In such a case, the impairment test is performed pursuant to IAS 36 according to the principles explained for intangible assets. Where an impairment is to be made, the remaining useful life of the asset may be adjusted accordingly. If the reasons for a previously recognised impairment have ceased to exist, such impairment losses are reversed, in which case such reversal may not exceed the carry- ing amount that would have resulted if no impairment had been recognised in the previous periods. Land is not depreciated. All other assets are depreciated using the straight-line method, with costs being depreciated over the expected useful lives of the assets so as to write down the value of the assets to their residual carrying amount as follows: Buildings Machinery and equipment Other plant and equipment 33¹/3 years 5 to 15 years 3 to 12 years The net book values and useful economic lives are reviewed at each balance sheet date and adjusted where applicable. Gains and losses on the disposal of assets are measured as the difference between the disposal proceeds and the carrying amount and recognised through profit or loss. 2.6 Government grants Government grants are recognised at fair value if it can be assumed with reasonable assurance that the grant will be received and that the Group has satisfied the necessary conditions for this. Government grants for investments are deducted from cost to arrive at the carry- ing amount for the assets to which they relate. They are distributed as a reduction in expenses over the expected useful life of the related assets using the straight-line method. Such grants are granted to hospitals within the framework of investment finance legislation. Grants not yet used for their intended purpose are stated under “Other liabilities” at the balance sheet date. Government grants are recognised on a systematic basis either in profit or loss, and during periods in which the Company applies cor- responding expenditures which the government grants are intended to cover as expenses. RHÖN-KLINIKUM AG | Annual Report 2022 95

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Accounting policies consideration, discounted cash flow methods, as well as option price models which make use as far as possible of market data and as little as possible of individual company data. On each balance sheet date it is reviewed whether any losses incurred or already expected losses are to be recognised. Unless the simplified impairment approach is applied to trade receivables, an additional dif- ferentiation is made as to whether or not the default risk of financial assets has materially deteriorated since their acquisition. If the default risk has deteriorated significantly (e.g. if the financial asset can no longer be allocated to the investment grade rating category), all expected losses as of that point in time are recognised over the entire term. Otherwise, only those losses expected over the term of the instrument are taken into account which result from future potential loss events within the next twelve months. Within the Group of RHÖN-KLINIKUM AG, the general impairment model is essentially applied to fixed deposit investments. In this regard, the expected credit loss is calculated taking into account external rat- ings, rates of insolvency as well as future-oriented information on credit default swaps (CDS). 2.8.1 Assets measured at fair value through profit and loss According to IFRS 9, financial assets are subject to mandatory mea- surement at fair value through profit or loss if they are held neither as part of a business model whose purpose consists in holding assets to collect contractual cash flows, nor as part of a business model whose purpose is fulfilled if contractual cash flows are collected and financial assets are sold. Moreover, financial assets are to be measured at fair value through profit or loss if they do not fulfil the cash flow conditions as defined in IFRS 9. At RHÖN-KLINIKUM AG, no assets in the form of debt capital instruments that could be allocated to this category exist. 2.8.2 Assets measured at fair value directly in equity (fair value through other comprehensive income, without recycling) Investments in equity instruments do not fulfil the cash flow condi- tions as defined in IFRS 9; they are principally to be measured at fair value. For equity instruments not held for trading, an entity has the irrevocable right on initial recognition to avail itself of the fair-value OCI option. Within the Group of RHÖN-KLINIKUM AG, equity invest- ments in the amount of € 13.3 million (previous year: € 17.5 million) are measured at fair value (fair value through other comprehensive income, without recycling). 2.8.3 Assets measured at amortised cost Financial assets held as part of a business model whose purpose consists in holding assets to collect the contractual cash flows are measured at amortised cost provided that the assets also fulfil the cash flow conditions as defined in IFRS 9. When assessing whether cash flows are realised through collection of the contractually agreed payments from the financial asset, the frequency and scope of the sales in earlier periods are to be consid- ered, furthermore whether the assets sold were about to mature, as well as the reasons for such sales and the expectations with respect to the future sales activities. Within the Group of RHÖN-KLINIKUM AG, trade receivables, other financial assets as well as cash and cash equivalents are allocated to this category. 2.8.4 Assets measured at fair value directly in equity (fair value through other comprehensive income, with recycling) This category covers financial assets which fulfil the cash flow condi- tions as defined in IFRS 9 and whose purpose consists in collecting contractual cash flows and selling financial assets. Currently, no such financial assets exist at RHÖN-KLINIKUM AG. Investment property 2.9 Investment properties comprise land and buildings which are held for the purpose of generating rental income or for achieving capital gains, and which are not used for the company’s own provision of services, for administrative purposes or for revenues within the scope of ordinary operations. Investment properties are measured at cost less cumulative depreciation. Since RHÖN-KLINIKUM AG or its subsidiaries retain beneficial owner- ship in leased properties as lessor (operating lease), these properties are identified as such and reported separately in the balance sheet. Leased assets are recognised at cost and depreciated in accordance with the accounting principles for property, plant and equipment. Lease income is recognised on a straight-line basis over the term of the lease. RHÖN-KLINIKUM AG | Annual Report 2022 97

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Accounting policies or loss, no deferred tax is recognised. Deferred taxes are measured subject to the tax rates (and tax laws) that apply or have been sub- stantively enacted on the balance sheet date and that are expected to apply when the deferred tax asset is realised or the deferred tax liability is settled. Deferred taxes have been calculated using a cor- porate income tax rate of 15.0% (plus the 5.5% solidarity surcharge on corporate income tax). Deferred tax assets are recognised to the extent it is probable that they will result in a tax benefit when offset against taxable profits. Deferred tax liabilities in connection with temporary differences arising from equity interests in subsidiaries are always recognised unless the point in time of the reversal of the temporary differences can be controlled by the Group and a reversal of the temporary differences is not probable in the foreseeable future. 2.16 Employee benefits 2.16.1 Pension obligations and other long-term benefits due to employees Various pension plans exist within the Group. These plans are financed by payments to insurance companies or pension funds or by rec- ognising provisions (direct commitments) whose amount is based on actuarial calculations. The Group has both defined benefit and defined contribution pension plans. A defined contribution plan is a pension plan under which the Group pays fixed contributions into a separate entity (insurance company or pension fund). The possibility of claims being asserted against the Group for payment of additional contributions exists only within the scope of subsidiary liability. Since RHÖN-KLINIKUM AG regards the risk of default of an insurance company or pension fund as extremely low, such commitments are accounted for as defined contribution plans. For defined contribution plans the Group pays contributions to state or private pension insurance plans based on statutory or contractual obligations. The Group has no further payment obligations other than the payment of the contributions. The contributions are recognised in personnel expenses when due. A defined benefit plan is a pension plan that does not fall under the definition of a defined contribution plan. It typically stipulates the amount of pension benefits that an employee will receive on retire- ment which is usually dependent on one or several factors such as age, length of service and salary. The provision stated in the balance sheet for defined benefit plans is equal to the present value of the defined benefit obligation (DBO) at the balance sheet date. The DBO is calculated annually by an inde- pendent actuary using the projected unit credit method. The present value of the DBO is calculated by discounting the expected future cash outflows with the interest rate of high quality corporate bonds issued in the currency in which the benefits are paid and whose terms are consistent with those of the pension obligation. Actuarial gains and losses resulting from changes in actuarial assump- tions and/or from discrepancies between earlier actuarial assump- tions and the actual development are recognised directly at equity in the period in which they occur giving due regard to deferred tax. In this way the balance sheet – after deduction of any existing plan assets – shows the full scope of the obligations avoiding fluctuations in expenses that may arise in particular in the case of changes in the calculation parameters. The actuarial gains and losses recognised in the respective reporting period are shown separately as “revaluations of defined benefit pension plans” in the statement of comprehensive income. Pursuant to IAS 19, past service cost, i.e. all changes in benefits diminishing the defined benefit obligation, are fully recognised in the income statement at the time of the plan modification. Multi-employer plans On the basis of collective agreements, the Group pays contributions to the Federal and State Pension Scheme (VBL) and other public service pension schemes (Bayerische Versorgungskammer-Zusatzversorgung, BVK) for a certain number of employees. The supplementary pension schemes are public-law corporations or institutions. The contributions are paid on a pay-as-you-go (PAYGO) basis. This financing structure carries the risk of rising contributions through the levy of reform imposts that may be charged unilaterally or disproportionately to employers. RHÖN-KLINIKUM AG | Annual Report 2022 99

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Accounting policies tender the interests to RHÖN-KLINIKUM AG in each case after five years, for the first time as at 31 December 2020. Moreover, the option of returning the interests on termination of the service relationship existed. The interests were measured at fair value, but at least at their nominal value. The interests were not freely disposable. Current and former members of the Board of Management tendered their inter- ests with effect from 31 December 2020. Payment of the purchase prices of € 0.4 million was made in 2021. The fair value calculation was once again adjusted in 2022. The result for the period of the reporting year includes € 0.3 million (previous year: € 0.0 million) in this connection. 2.17 Provisions Provisions for restructuring and legal obligations are recognised when the company has an obligation as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation in the future, and the value of the outflow of resources can be reliably determined. Restructuring provi- sions essentially include the costs of early termination of employment contracts with employees. Where there are a number of similar obligations, the probability of an outflow of resources being required for settlement is assessed based on an aggregate view of such similar obligations. A provision is also recognised if the probability of outflow for any one of such obligations is deemed to be small. Provisions are measured as the present value of the payments expected to be required to settle the obligation. For this purpose, discounting is effected at a risk-free interest rate. Risk premiums are taken into account in the measurements of the future cash outflows. Increases in the value of provisions based on interest effects reflecting the passage of time are recognised as interest expense in the income statement. 2.18 Revenue recognition Revenue is recognised at the fair value of the consideration received for the provision of services and for the sale of products. Revenue from intra-group goods and services is eliminated by way of consol- idation. Revenue is recognised as follows. 2.18.1 Inpatient and outpatient hospital services Hospital services are recognised in the financial year in which the services are performed by reference to the stage of completion as a proportion of the total services to be performed. Charges agreed with the payers are essentially invoiced at fixed rates irrespective of the duration of stay. In certain segments daily hospital and nursing rates are invoiced. In the outpatient area, the individual services and medical aids are invoiced based on the schedules of benefits applic- able to the respective area. Hospital services are limited in terms of their volume as part of an agreed budget. As a result, service volumes exceeding the budget and service volumes falling short of the budget are to be mutually offset under statutory provisions. Budget-restricting provisions are also being applied in the outpatient area. Further notes are provided under point 3.2 “Revenue recognition”. 2.18.2 Interest income Interest income is recognised on a pro rata basis using the effective interest method. 2.18.3 Income from distribution and dividends Dividend income is recognised when the right to receive payment is established. 2.19 Leases Standard IFRS 16 defines a lease as a contract which conveys the right to use an asset for a period of time in exchange for consideration. As a rule, every lease is to be recognised with the lessee on the balance sheet in the form of a right of use and a lease liability. The lease liability is measured in accordance with the lease payments outstanding discounted with the incremental borrowing rate if it is not possible to calculate the interest rate implicit in the lease. The present value calculation is therefore as a rule based on the incre- mental borrowing rates. The right of use as a general rule is measured at the amount of the lease liability plus any initial direct cost. During the lease term, the right of use is to be depreciated and the lease liability updated using the effective interest method and taking into account the lease payments. For leases with a term of twelve months maximum as of 1 January 2019 as well as leases relating to low-value assets, no right of use and no lease liability will be applied in the balance sheet and the lease payments will continue to be recognised as an expense as thus with a negative effect on EBITDA in the income statement. 2.20 Costs of borrowing If borrowing takes place, the costs of borrowing are deducted from the corresponding items and are distributed using the RHÖN-KLINIKUM AG | Annual Report 2022 101

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Accounting policies | Critical estimates and assessments in accounting and valuation In July 2019, RHÖN-KLINIKUM AG placed a registered bond in the amount of € 60.0 million with a term of 20 years. In October 2018 a promissory note in the amount of € 100.0 million was issued, which was redeemed in financial year 2020 in the amount of € 10.0 million. The tranches exclusively bearing fixed interest with bullet maturities have terms of five, seven and ten years. The registered bond and the promissory note are subject to a change-of-control clause. The funds collected from both transactions are being used for general corporate finance. In 2017 a syndicated line of credit in the amount of € 100.0 million was entered into which was lowered to € 88.0 million in financial year 2020. As at the balance sheet date, this line had not been utilised (previous year: no utilisation). As already in the previous year, no monitoring of interest rate risks was performed in financial year 2022 by means of sensitivity analyses given the low risk. 2.22.5 Management of equity and debt The aim of the Management with regard to the handling of equity and debt is to adopt a strict policy of matching maturities (horizontal balance sheet structure) of the source and use of funds. Non-current assets should be funded on a long-term basis. The items of equity and non-current liabilities shown in the balance sheet are included under the source of long-term funds. This ratio should be at least 100%, and amounted to 139.1% in the year under review (previous year: 132.0%). Long-term appropriation of funds relates to financial assets and property, plant and equipment. Although given the per- sonnel cost ratio of more than 50% the Group of RHÖN-KLINIKUM AG is frequently attributed to the services sector, our business model has a long-term focus and is for the most part investment-driven. As at 31 December 2022, 73.4% (previous year: 73.5%) of investments at the Group level was backed by equity. Group growth is also managed by way of appropriate equity mea- sures through resolutions on the appropriation of profits for the con- solidated companies. If debt capital is used, the Management focuses on the following management ratios for minimising risks. The aim is to limit the ratio between net financial debt (= financial liabilities less cash and cash equivalents) and EBITDA to a maximum 3.5-fold multiple. 3 | CRITICAL ESTIMATES AND ASSESSMENTS IN ACCOUNTING AND VALUATION All estimates and assessments are subject to ongoing review and are based on past experience and other factors, including expectations with respect to future events which appear reasonable under the given circumstances. The Group makes assessments and assumptions about the future. The estimates derived from these of course only rarely reflect actual future circumstances. These uncertainties in particular concern the following: – the planning parameters taken as a basis of the impairment test for goodwill, – assumptions relating to revenue recognition, – assumptions and probabilities for determining provisions in particular, – assumptions relating to the default risk of trade receivables, and – assumptions relating to the recognition and measurement of income tax. The estimates and assumptions that entail a significant risk of a sub- stantial adjustment in carrying amounts of assets and liabilities during the next financial year are discussed in the following. Estimated impairment of goodwill 3.1 To determine goodwill at fair value less costs to sell, the oper- ating cash flows of the individual hospitals, with their inpatient, semi- inpatient and outpatient care structures, were discounted at the weighted average cost of capital (WACC) after tax of 6.78% ( previous year: 5.20%). The carrying amounts do not exceed fair value less cost of sale. Based on this calculation, no impairment require- ment was ascertained. Key assumptions having a substantial influ- ence on fair value less costs to sell are WACC and the average EBIT margin. For further details, reference is made to our Note under 6.1. For the cash generating units, the recoverable amount is equal to the carrying amount as of an assumed cost of capital rate of 7.4% ( previous year: 6.5%). RHÖN-KLINIKUM AG | Annual Report 2022 103

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Critical estimates and assessments in accounting and valuation In this context, € 77.6 million (previous year: € 61.7 million) was reported within revenues in financial year 2022 as payment relating to COVID-19 legislation. These revenues are primarily attributable to income from keeping hospital beds available. Furthermore, € 3.2 mil- lion (previous year: € 1.7 million) were reported under other income as well as € 0.3 million (previous year: € 0.9 million) under the employee expense item. Income taxes 3.3 Estimates are required for the recognition of tax provisions as well as deferred tax items. For determining the actual value of deferred tax assets, it is essential to assess the probability of the reversal of the valuation differences and the extent to which it is possible to use the tax loss carry-forwards that led to the recognition of deferred tax assets. This depends on the generation of future taxable profits during the periods in which tax valuation differences are reversed and tax loss carry-forwards can be utilised. Uncertainties exist with regard to the interpretation of complex tax regulations as well as the amount and timing of future taxable income that result in changes in the tax income or expense in future periods. The Group recognises adequate provisions for the possible consequences of audits by the tax authorities. The amount of such provisions is based on factors such as experience from past tax audits and differing interpretations of substantive tax law by the taxable entity and the competent tax authorities on specific issues. estimates are made with reference to the complaint rate of the MD and, based on empirical values, corresponding corrections in rev- enues taken into account for this. The final results from the reviews of the MD in turn have an influence on the income compensation for the respective financial year. When the fourth wave of the COVID-19 pandemic hit in the autumn of 2021, the German legislator in November 2021 initially introduced a new care surcharge for COVID-19 patients admitted from 1 Novem- ber 2021 to 19 March 2022. Its amount was calculated based on the average inpatient duration of stay of COVID-19 patients and was staggered by the respective daily lump sum amounts on which the relief payments were based. Just before the end of 2021, the German Federal Parliament (Bundestag), with the Act Strengthening Vaccine Protection against COVID-19 and Amending Further Regulations in connection with the COVID-19 Pandemic (Gesetz zur Stärkung der Impfprävention gegen COVID-19 und zur Änderung weiterer Vorschriften im Zusammenhang mit der COVID-19-Pandemie), more- over decided to once again grant hospitals, with retroactive effect to 15 November 2021, relief payments for beds kept available if they postpone elective operations or procedures to make capacities avail- able for COVID-19 patients. This provision, which was initially limited in term to 31 December 2021, was initially extended to 19 March 2022 by the Second Regulation Amending the Regulation on Further Measures to Safeguard the Economic Viability of Hospitals (zweite Verordnung zur Änderung der Verordnung zur Regelung weiterer Maßnahmen zur wirtschaftlichen Sicherung der Krankenhäuser). By the Regulation Amending the Regulation on Further Measures to Safe- guard the Economic Viability of Hospitals and Amending the Hygiene Flat Fee Regulation (Verordnung zur Änderung der Verordnung zur Regelung weiterer Maßnahmen zur wirtschaftlichen Sicherung der Krankenhäuser und zur Änderung der Hygiene pauschaleverordnung) published on 29 March 2022, an extension beyond 19 March 2022 of these relief payments was adopted pursuant to section 21 (1b) of the KHG and of the care surcharge pursuant to section 21a of the KHG. Specifically, the current Regulation provided for an extension of the relief payments until 18 April 2022 and an extension of the care surcharge for the last time until 30 June 2022. RHÖN-KLINIKUM AG | Annual Report 2022 105

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Notes to the consolidated income statement 5 | NOTES TO THE CONSOLIDATED INCOME STATEMENT 5.2 Other income Other operating income comprises: 5.1 Revenues The development of revenues by business areas and geographical regions was as follows: in € million Income from services rendered Income from grants and other allowances Income from indemnification payments/ other reimbursements Other 2022 2021 194.4 13.3 1.8 10.6 220.1 180.3 8.9 1.2 8.1 198.5 in € million Business areas Acute hospitals Rehabilitation hospitals Medical care centres Regions Bavaria Thuringia Brandenburg Hesse 2022 2021 1,391.4 1,349.6 30.0 24.7 27.6 24.8 1,446.1 1,402.0 301.3 193.5 163.7 787.6 287.6 189.4 163.0 762.0 1,446.1 1,402.0 According to IFRS 15, revenue proceeds are revenues generated from the provision of services and in financial year 2022 rose by € 44.1 million or 3.1% to reach € 1,446.1 million. Of that, our acute and rehabilitation hospitals accounted for € 1,421.4 million (previous year: € 1,377.2 million) and the medical care centres for € 24.7 million (previous year: € 24.8 million). The revenues of financial year 2022 include an amount of € 77.6 million (previous year: € 61.7 million) in relief payments brought in by legislation, including revenue-offsetting claims (previous year: revenue-offsetting obligations) in connection with the COVID-19 pandemic. The reimbursements are mainly attributable to relief amounts for beds kept available as well as care surcharges paid to hospitals for extraordinary charges as a result of the coronavirus. Income from services rendered includes income from ancillary and incidental activities amounting to € 185.7 million (previous year: € 171.8 million) as well as income from rental and lease agreements amounting to € 8.7 million (previous year: € 8.5 million). The Group received grants and other allowances as compensation for certain purpose-tied expenses in connection with publicly funded measures (e.g. costs of personnel and materials for research and teaching). The rise in other income by € 21.6 million or 10.9% is mainly attributable to the higher income from ancillary and incidental activities resulting, among other things, from higher sales of drugs and cytostatics as well as higher reimbursements for training. Moreover, reimbursements under legislation in connection with the COVID-19 pandemic are included at the amount of € 3.2 million (previous year: € 1.7 million) as well as refunds of the legislature in connection with the compensation for increased energy expenses from resources of the health fund at the amount of € 2.0 million (previous year: € 0.0 million). RHÖN-KLINIKUM AG | Annual Report 2022 107

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Notes to the consolidated income statement Other expenses saw an increase from € 147.3 million by € 16.9 million to € 164.2 million. The increase is essentially attributable to higher payments for training facilities, maintenance and servicing requirements, in addition to higher personnel and continued training expenses as well as insurance expenses. 5.7 Result from impairment on financial assets The result from the impairment on financial assets in the amount of € 0.0 million (previous year: negative result of € 0.2 million) results from the adoption of IFRS 9, which among other things governs the future expected losses of financial assets. The improvement in the negative result recorded in the same period of previous year, tak- ing account of higher receivables owed from payers, is essentially attributable to lower expected credit losses calculated on the basis of the sovereign default risk for Germany. Regarding the default risk of financial assets, we refer to the comments on the finance result. 5.8 Research costs Research activities relate primarily to process optimisations in the area of inpatient hospital care and not to making marketable products. The research results are therefore generally produced as a result of or in objective connection with the activities of healthcare provision. For this reason, differentiating and measuring these in isolation is possible only to a very limited extent. Depending on the volume of costs to be attributed to research activities, annual research expenditure is roughly estimated to be within a range of 0.1% to 0.2% of revenues. They are primarily accounted for by personnel expenses and other expenses. As part of the takeover of the two university and research sites Giessen and Marburg, in addition we committed ourselves to provide funding to the two medical faculties in an amount of at least € 2.0 million p.a. Finance result – net 5.9 The finance result is shown as follows: in € million Result of investments accounted for using the equity method Income of investments accounted for using the equity method Expense of investments accounted for using the equity method Finance income Bank balances Interest income from tax assets Other interest income Finance expenses Liabilities to banks Interest expenses from tax liabilities Other interest expenses Result of impairment on financial investments as defined in IFRS 9 Income from impairment on financial investments Expense from impairment on financial investments 2022 2021 0.1 – 0.1 1.1 0.0 0.2 1.3 –2.3 –0.9 –0.9 –4.1 0.2 – 0.2 –2.5 0.1 – 0.1 0.1 0.2 0.2 0.5 –2.1 –0.2 –0.9 –3.2 – –0.6 –0.6 –3.2 The negative finance result improved in financial year 2022 by € 0.7 million to € 2.5 million. In this regard it has to be taken into account that an income item from the impaired financial assets under IFRS 9 was recognised in the amount of € 0.2 million (previous year: expense of € 0.6 million). RHÖN-KLINIKUM AG | Annual Report 2022 109

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Notes to the consolidated income statement 5.11 Non-controlling interests in profit This is the share of profit attributable to minority shareholders. The number of shares is unchanged. For disclosures on equity, please refer to the Note 6.12. 5.12 Earnings per share Earnings per share in accordance with IAS 33 is calculated using the share of consolidated profit attributable to the shareholders of RHÖN-KLINIKUM AG and the weighted average number of shares in issue during the year. Earnings per share are calculated as follows: The following table sets out the development in ordinary shares outstanding: Share in consolidated profit (€ ’000) (previous year) Weighted average number of shares outstanding, in thousands No. of shares on 1 Jan. 2022 No. of shares on 31 Dec. 2022 (previous year) Earnings per share in € (previous year) Ordinary shares 25,144 28,295 66,938 (66,938) 0.38 (0.42) Non-par shares Treasury shares 66,962,470 66,962,470 –24,000 –24,000 66,938,470 66,938,470 Diluted earnings per share are identical to undiluted earnings per share, as there were no stock options or convertible debentures out- standing at the respective balance sheet dates. RHÖN-KLINIKUM AG | Annual Report 2022 111

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Notes to the consolidated balance sheet The weighted cost of capital of a potential investor from the health- care sector is used as the discount rate at the time of measurement, taking into account the tax shield arising from theoretical debt financ- ing (“tax shield”). This discount rate was defined at 6.78% for 2022 (previous year: 5.20%). Significant goodwill relates to the following cash generating units: The table below shows the assumptions of long-term growth rates for revenues by which the Company planning is projected by a further five years which were used in the impairment test of the business generating units to which material goodwill was attributed to deter- mine fair value less cost of sale: in € million Units in % 31 Dec. 2022 31 Dec. 2021 Universitätsklinikum Gießen und Marburg Zentralklinik Bad Berka RHÖN-KLINIKUM Campus Bad Neustadt Other goodwill of less than € 5.0 million 137.5 16.6 6.5 4.9 137.5 16.5 6.5 4.7 Balance sheet value 165.5 165.2 For the calculation of fair value of the business generating units less cost of sale, cash flows were forecast on the basis of past experience, current operating results and best-possible estimates of future man- agement performance as well as market assumptions. The values in use could not be taken as a basis because the carrying amounts are already exceeded by fair values less cost of sale. The calculated fair value for the business generating units was attributed to level 3 of the hierarchy levels of fair values. Fair value less cost of sale is primarily defined by the terminal value (present value or perpetual annuity) which is particularly sensitive to changes in assumptions on the long- term growth rate of revenues and on the discount rate. Whereas the discount rate was defined uniformly for all business generating units, the growth rate is defined individually per entity. The discount rate reflects the current market assessment of the entities’ specific risks. The growth rates take account of external macroeconomic data and sector-specific trends. For planning purposes, the units accounting for the main portion of goodwill are assumed to have a homogenous structure. 2022 2021 Long-term growth rate – revenues 3.00 3.00 Long-term growth rate – revenues 3.00 3.00 WACC 6.78 6.78 WACC 5.20 5.20 3.00 6.78 3.00 5.20 Universitäts- klinikum Gießen und Marburg Zentralklinik Bad Berka RHÖN-KLINIKUM Campus Bad Neustadt The assumptions for the other business generating units are comparable. The values of revenues in the ten-year planning period of the groups of cash generating units to which material goodwill was attributed are based on average organic growth rates of between 2.8% and 3.4% (previous year: 2.3% and 3.1%). In connection with the impairment test, a sensitivity analysis was also performed. Within the test the following assumptions were used: – EBIT declines by 10% – WACC increase by 0.5% As a result of the sensitivity analysis it was determined that a decline in EBIT by 10% does not result in any impairment requirement ( previous year: no impairment requirement). An increase in WACC by 0.5% likewise does not give rise to an impairment requirement (previous year: no impairment requirement). RHÖN-KLINIKUM AG | Annual Report 2022 113

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Notes to the consolidated balance sheet During the financial year, borrowing costs of € 0.8 million (previous year: € 1.0 million) were related to financing the acquisition or produc- tion of qualifying assets and were recognised in additions to property, plant and equipment. An average interest rate of 1.9% (previous year: 2.4%) was used, which reflects the Group’s general costs of borrowing from banks. Similar to the previous year, the Group has no registered charges on real property as collateral for bank loans. Public grants related to assets are deducted from the cost of the asset for which they are given, reducing the depreciation over the period. The deducted amortised amount of assistance granted under the Hospital Financing Act (Krankenhausfinanzierungsgesetz, KHG) and which was invested in line with the applicable conditions totals € 144.5 million (previous year: € 151.7 million). To secure conditionally repayable single grants under the KHG (e.g. for the construction of new hospitals or major extensions) totalling € 1.5 million (previous year: € 1.7 million), the Group holds registered charges on real prop- erty in the amount of € 4.1 million (previous year: € 4.1 million). There are no reasons to assume that these grants will have to be repaid. Buildings, technical equipment and medical equipment include as at 31 December 2022 rights of use pursuant to IFRS 16 in which the Group is the lessee. The rights of use are as follows: in € million Land and buildings Operating and office equipment Cost 1 Jan. 2022 Addition to consolidated companies Additions Disposals 31 Dec. 2022 Cumulative depreciation and impairment 1 Jan. 2022 Depreciation Disposals 31 Dec. 2022 Balance sheet value as at 31 Dec. 2022 5.6 0.0 1.0 0.1 6.5 1.8 0.9 0.1 2.6 3.9 13.4 0.0 0.8 1.2 13.0 7.2 2.4 1.0 8.6 4.4 Total 19.0 0.0 1.8 1.3 19.5 9.0 3.3 1.1 11.2 8.3 in € million Land and buildings Operating and office equipment Cost 1 Jan. 2021 Addition to consolidated companies Additions Disposals 31 Dec. 2021 Cumulative depreciation and impairment 1 Jan. 2021 Depreciation Disposals 31 Dec. 2021 Balance sheet value as at 31 Dec. 2021 4.2 0.0 1.7 0.3 5.6 1.2 0.9 0.3 1.8 3.8 13.9 0.0 0.7 1.2 13.4 5.8 2.5 1.1 7.2 6.2 Total 18.1 0.0 2.4 1.5 19.0 7.0 3.4 1.4 9.0 10.0 6.3 Deferred tax assets Deferred tax assets and liabilities are netted if there is an enforceable right to offset current tax assets against current tax liabilities and if the deferred taxes exist against the same tax authority. The following amounts were netted: in € million Tax loss carry-forwards Property, plant and equipment/ intangible assets Interest-bearing liabilities Recognition differences for subsidiaries Other assets and liabilities Total Balance sheet value 31 Dec. 2022 31 Dec. 2021 Assets Liabilities Assets Liabilities 0.0 0.0 0.0 0.0 9.0 9.0 0.4 0.0 6.5 0.1 1.3 0.7 8.6 0.1 0.0 0.0 0.0 9.7 9.8 1.1 0.0 6.7 0.2 1.0 0.8 8.7 RHÖN-KLINIKUM AG | Annual Report 2022 115

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Notes to the consolidated balance sheet 6.5 Other financial assets (non-current) Other non-current financial assets break down as follows: in € million in € million Participating interests 31 Dec. 2022 31 Dec. 2021 13.3 13.3 17.5 17.5 The equity interests relate to interests held by the company RHÖN-Innovations GmbH in the companies Inovytec Medical Solutions Ltd., Telesofia Medical Ltd. and CLEW Medical Inc. The interests in Tiplu GmbH and Siebensachen GmbH were sold in 2022. The interests are measured at fair value in accordance with IFRS 9. The investments are measured at fair value directly in equity (fair value through other comprehensive income, without recycling). The carrying amount of € 13.3 million (previous year: € 17.5 million) corresponds to the maximum default risk. Moreover, € 0.0 million (previous year: € 0.0 million) relates to imma- terial equity interests which are measured at fair value. Like at the previous year’s balance sheet date, no long-term fixed deposit investments and according no impairments were to be r ecognised according to IFRS 9 at the balance sheet date of 31 December 2022. Inventories 6.6 Inventories in the amount of € 33.3 million (previous year: € 33.1 million) are attributable to raw materials, consumables and sup- plies and mainly consist of medical supplies. Impairments of € 3.7 million (previous year: € 3.7 million) were effected. All inven- tories are owned by RHÖN-KLINIKUM AG and the companies affiliated with RHÖN-KLINIKUM AG. There are no assignments or pledges of inventories. 6.7 Trade receivables As at the balance sheet date of 31 December 2022, we report trade receivables in the amount of € 228.6 million (previous year: € 212.9 million). The fair values of trade receivables essentially correspond to their carrying amounts since they are primarily short-term in character. Trade receivables as well as impairments within the meaning of IFRS 9 show the following maturity structure as at the balance sheet date of 31 December 2022: RHÖN-KLINIKUM AG | Annual Report 2022 Impairment matrix 31 Dec. 2022 Not overdue Between 0 and 30 days overdue Between 31 and 90 days overdue Between 91 and 180 days overdue More than 180 days overdue Total Gross carrying amount Expected credit loss 191.7 16.1 8.9 5.7 7.2 229.6 0.3 0.1 0.1 0.3 0.2 1.0 Trade receivables as well as impairments within the meaning of IFRS 9 had the following maturity structure as at the balance sheet date of 31 December 2021: in € million Impairment matrix 31 Dec. 2021 Not overdue Between 0 and 30 days overdue Between 31 and 90 days overdue Between 91 and 180 days overdue More than 180 days overdue Total Gross carrying amount Expected credit loss 176.8 11.5 11.4 6.8 7.4 213.9 0.3 0.1 0.4 0.1 0.1 1.0 The development of impairments pursuant to IFRS 9 recognised under the item “Trade receivables” is shown in the table below: in € million 2022 2021 Impairment As at 1 Jan. pursuant to IFRS 9 Changes in consolidated companies Allocation Utilisation Write-back Currency translation difference As at 31 Dec. pursuant to IFRS 9 1.0 – 1.0 – 1.0 – 1.0 0.8 – 1.0 – 0.8 – 1.0 117

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Notes to the consolidated balance sheet The remaining other financial assets (current, not including fixed deposits) as well as the corresponding impairments as defined within the meaning of IFRS 9 had the following maturity structure as at the balance sheet date of 31 December 2021: Within the Group, settlement receivables due from and settlement liabilities to the payers under fee/budget agreements of the current year and the previous years are stated on a netted basis. On a gross basis, the statement is as follows: in € million in € million Gross carrying amount Expected credit loss 31 Dec. 2022 31 Dec. 2021 Impairment matrix 31 Dec. 2021 Not overdue Between 0 and 30 days overdue Between 31 and 90 days overdue Between 91 and 180 days overdue More than 180 days overdue Total 57.6 0.5 0.1 0.1 0.1 58.4 0.1 0.1 0.0 0.0 0.1 0.3 The development of the impairments recognised under the item “Other financial assets (current)” pursuant to IFRS 9 is shown in the table below: in € million Impairment As at 1 Jan. pursuant to IFRS 9 Changes in consolidated companies Allocation Utilisation Write-back Currency translation difference As at 31 Dec. pursuant to IFRS 9 2022 2021 1.5 – 1.2 – 1.5 – 1.2 0.9 – 1.5 – 0.9 – 1.5 Of the impairments as at the balance sheet date in the amount of € 1.2 million (previous year: € 1.5 million), € 1.0 million (previous year: € 1.2 million) is attributable to fixed deposits. Receivables according the KHEntgG (gross) Liabilities according the KHEntgG (gross) Balance sheet value 147.9 –42.8 105.1 94.3 –43.8 50.5 Regarding the statement on a gross basis of the corresponding lia- bilities in accordance with the KHEntgG, please refer to the section “Other financial liabilities”. 6.9 Other assets (current) Of other current assets in the amount of € 12.5 million (previous year: € 10.4 million), essentially € 6.1 million (previous year: € 6.3 million) is attributable to prepaid expenses, in particular maintenance contracts relating to hardware and software, as well as € 5.3 million (previous year: € 3.6 million) to reimbursement claims against insurers under liability claims. 6.10 Current income tax assets Current income tax assets essentially include claims against tax authorities for reimbursement of corporate income tax. 6.11 Cash and cash equivalents in € million Cash with banks and cash on hand Short-term bank deposits 31 Dec. 2022 31 Dec. 2021 77.3 0.0 77.3 126.0 0.3 126.3 The decline in cash with banks and cash on hand is attributable to an increase in short-term fixed deposit investments as a result of an improved interest rate environment for time deposits relative to over- night money deposits. As far as possible, freely disposable funds were reallocated at matching maturities into fixed deposit investments with a remaining term of < 1 year (> 3 months) and reported under the item “Other financial assets (current)”. In the previous year, there were short-term bank balances with an initial term of < 3 months. The effective interest rate for these bank balances was 0.00%. The average remaining term of these deposits was 30 days. RHÖN-KLINIKUM AG | Annual Report 2022 119

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Notes to the consolidated balance sheet 6.13 Financial liabilities in € million 31 Dec. 2022 31 Dec. 2021 Residual term > 1 year Residual term > 1 year Non-current financial liabilities Liabilities to lenders Total non-current financial liabilities Current financial liabilities Liabilities to lenders Total current financial liabilities 141.7 141.7 – – Total financial liabilities 141.7 – – 8.0 8.0 8.0 148.6 148.6 – – 148.6 – – 1.0 1.0 1.0 was redeemed in financial year 2020 in the amount of € 10.0 million. The tranches exclusively bearing fixed interest with bullet maturities have terms of five, seven and ten years. The registered bond and the promissory note are subject to a change-of-control clause. The funds collected from both transactions are being used for general corpor- ate finance. In 2017 a syndicated line of credit in the amount of € 100.0 million was entered into which was lowered to € 88.0 million in financial year 2020. As at the balance sheet date, this line had not been utilised. The syndicated loan is subject to a financial covenant. This financial ratio limits net financial debt to a maximum of 3.5 times EBITDA. The financial ratio was complied with by RHÖN-KLINIKUM AG in financial year 2022 (previous year: complied with). The funds collected are used for general corporate finance to ensure sufficient funds for investments planned in the medium- to short- term. The reported financial liabilities amounting to € 150.0 million (previous year: € 150.0 million) decrease by the costs incurred in con- nection with the borrowing in the amount of € 1.4 million (previous year: € 1.4 million). In July 2019, RHÖN-KLINIKUM AG placed a registered bond in the amount of € 60.0 million with a term of 20 years. In October 2018 a promissory note in the amount of € 100.0 million was issued, which The contractual interest adjustment dates relating to the inter- est-bearing liabilities are as follows: in € million Fixed interest period ends Liabilities to lenders 2023–2026 2027 2028 > 2028 Interest on loans 1 Weighted interest rate. 31 Dec. 2022 31 Dec. 2021 Interest rate in %1 Nominal amount Carrying amount of loans Interest rate in %1 Nominal amount Carrying amount of loans 1.26 – 1.82 2.35 38.0 – 52.0 60.0 37.9 – 51.8 58.9 1.0 1.25 – 1.82 2.35 38.0 – 52.0 60.0 37.9 – 51.8 58.9 1.0 150.0 149.6 150.0 149.6 RHÖN-KLINIKUM AG | Annual Report 2022 121

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Notes to the consolidated balance sheet The commitments have a term of > 1 year. There are no reimburse- ment claims resulting from pension liability insurance policies entered into by reason of pension commitments to employees. The weighted average duration of the pension liabilities is two years (previous year: three years). The sensitivity of the pension obligations in terms of fluctuation range due to changes in the various actuarial valuation assumptions is shown in the table below: Change in assumption in percentage points Increase in assumption Reduction in assumption Change in assumption in percentage points Increase in assumption Reduction in assumption Impact on the commitment (%) as at 31 Dec. 2021 Interest rate Remuneration trend 0.2 0.2 Mortality +/– 1 year –0.6 0.6 0.1 0.6 –0.6 –0.1 Impact on the commitment (%) as at 31 Dec. 2022 Interest rate Remuneration trend 0.2 0.2 Mortality +/– 1 year The effects of the sensitivity were calculated using the same method as the obligations at the end of the year. In this regard, effects of a simultaneous change in several assumptions were not examined. Since the commitments remaining at the end of the financial year are capital commitments, no, or no material, changes result from the change in the pension trend; consequently, no disclosure of sensitivity in this regard was made. 0.0 0.0 0.0 0.0 0.0 0.0 6.15 Other provisions Other provisions developed as follows in the financial year: in € million Liability risks Other provisions 1 Jan. 2022 Use Reversal Allocation 31 Dec. 2022 of which < 1 year of which > 1 year 10.7 21.5 32.2 0.2 13.9 14.1 0.1 4.2 4.3 3.5 16.7 20.2 13.9 20.1 34.0 13.9 20.1 34.0 0.0 0.0 0.0 The provisions for liability risks relate to claims for damages by third parties. These compare with repayment claims from insurers in the amount of € 5.3 million (previous year: € 3.6 million) against insurers; these are shown under other assets (current). In the assessment of the Board of Management, the settlement of these liability events using the provisions will not entail any significant additional expenses. The timing of cash outflows from liability risks, which generally may occur in the short term, essentially depends on the course and outcome of specific liability cases. The other provisions include provisions for recovery risks in the amount of € 18.4 million (previous year: € 15.8 million) as well as for risk provisioning for legal and non-income-tax risks in the amount of € 1.7 million (previous year: € 5.7 million). RHÖN-KLINIKUM AG | Annual Report 2022 123

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Notes to the consolidated balance sheet The carrying amounts of the current financial liabilities recognised under this item correspond to their fair values. The carrying amounts of other non-current liabilities have been discounted using the effec- tive interest method on the basis of historical market rates. 6.18 Other liabilities in € million Similar to the previous year, the remaining non-current financial liabilities have a remaining term of less than five years. Of the figure stated for remaining non-current financial liabilities with remaining terms of less than five years, € 10.0 million (previous year: € 4.0 million) is attributable to the contractual intended payment obligations recognised as at the balance sheet date, € 3.8 million (previous year: € 5.6 million) to obligations arising from research grants owed to the universities in Giessen and Marburg as well as € 0.8 million (previous year: € 0.9 million) to other obligations. Within the Group, settlement receivables due from and settlement liabilities to payers under fee/budget agreements of the current year and the previous years are stated on a netted basis. Personnel liabilities Liabilities under KHG Operating taxes and social security contributions Deferred income Prepayments Other liabilities Other liabilities (non-financial instruments) 31 Dec. 2022 31 Dec. 2021 < 1 year > 1 year < 1 year > 1 year 79.4 48.8 13.6 3.4 0.6 10.6 0.0 0.0 0.0 0.0 0.0 0.0 79.7 27.1 14.0 9.8 0.4 10.0 0.0 0.0 0.0 0.0 0.0 0.0 156.4 0.0 141.0 0.0 in € million 31 Dec. 2022 31 Dec. 2021 Liabilities according to the KHEntgG (gross) Receivables according to the KHEntgG (gross) Balance sheet value 42.8 –42.8 0.0 43.8 –43.8 0.0 Regarding the statement on a gross basis of receivables in accordance with the KHEntgG on the assets side, please refer to the section “Other financial assets (current)”. Personnel liabilities relate in particular to performance-linked remuneration, obligations arising from still outstanding holiday leave entitlement as well as overtime obligations and on-call ser- vices. Moreover, severance payment obligations are recognised under this item. The liabilities under the KHG relate to government grants not yet used in accordance with the conditions for their use granted under state legislation for hospital financing as well as the Hospital Future Act (Krankenhauszukunftsgesetz, KHZG). The remaining liabilities essentially include third-party funds from, among other things, ongoing studies not yet appropriated. 6.19 Current income tax liabilities Current income tax liabilities in the amount of € 11.2 million (previ- ous year: € 14.6 million) comprise corporate income tax, solidarity surcharge and trade tax not yet assessed for the past financial year and previous years. 6.20 Derivative financial instruments As at the previous year’s balance sheet date, no derivative financial instruments exist. RHÖN-KLINIKUM AG | Annual Report 2022 125

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Notes to the consolidated balance sheet 31 Dec. 2022 of which financial instruments Carrying amount Fair value 31 Dec. 2021 of which financial instruments Carrying amount Fair value 13.3 13.3 0.0 0.0 561.3 77.3 141.7 20.2 14.6 5.6 70.0 8.0 11.6 8.7 2.9 13.3 13.3 0.0 0.0 561.3 77.3 141.7 20.2 14.6 5.6 70.0 8.0 11.6 8.7 2.9 638.6 13.3 0.0 243.0 13.3 13.3 0.0 0.0 561.3 77.3 119.6 14.4 14.4 – 70.0 7.8 8.6 8.6 – 638.6 13.3 0.0 220.4 17.5 17.5 0.0 0.0 436.8 126.3 148.6 17.6 10.5 7.1 72.5 1.0 12.1 9.0 3.1 17.5 17.5 0.0 0.0 436.8 126.3 148.6 17.6 10.5 7.1 72.5 1.0 12.1 9.0 3.1 563.1 17.5 0.0 241.6 17.5 17.5 0.0 0.0 436.8 126.3 158.4 10.9 10.9 – 72.5 1.0 9.0 9.0 – 563.1 17.5 0.0 251.8 RHÖN-KLINIKUM AG | Annual Report 2022 127

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Notes to the consolidated balance sheet 6.21.2 Net gains or losses by measurement category The net result by measurement category according to IFRS 9 for financial year 2022 is as follows: in € million Financial assets measured at amortised cost Total + = cost, – = income From subsequent measurement From share price gains At fair value Impairment 0.0 0.0 0.0 0.0 –0.2 –0.2 Net result 2022 13.0 13.0 From disposal 13.2 13.2 The net result by measurement category according to IFRS 9 for financial year 2021 is as follows: in € million Financial assets measured at amortised cost Total + = cost, – = income From subsequent measurement Net result From share price gains At fair value Impairment 0.0 0.0 0.0 0.0 0.8 0.8 From disposal 4.5 4.5 2021 5.3 5.3 RHÖN-KLINIKUM AG | Annual Report 2022 129

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Statement of cash flows In financial year 2022, financial liabilities changed as follows: in € million 31 Dec. 2021 Cash changes Non-cash changes Change in consolidated companies 31 Dec. 2022 Lease obligations Current financial liabilities Non-current financial liabilities Total liabilities from finance activities 10.2 1.0 148.5 159.7 –3.5 –1.0 – –4.5 1.8 8.0 –6.9 2.9 – – – 0.0 8.5 8.0 141.6 158.1 Financial liabilities changed in financial year 2021 as follows: in € million 31 Dec. 2020 Cash changes Non-cash changes Change in consolidated companies 31 Dec. 2021 Lease obligations Current financial liabilities Non-current financial liabilities Total liabilities from finance activities 11.2 0.9 148.5 160.6 –3.5 –0.9 – –4.4 2.5 1.0 0.0 3.5 – – – 0.0 10.2 1.0 148.5 159.7 RHÖN-KLINIKUM AG | Annual Report 2022 131

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Shareholdings in € ’000 Interest held in % Result for the year Equity 8.2 Other companies according to section 313 (2) No. 2 et seq. HGB in € ’000 50.0 1,025 153 Interest held in % Result for the year Equity 100.0 183 –9 4QD – Qualitätskliniken.de GmbH, Berlin1 20.0 217 –66 100.0 678 –10 CLEW Medical Inc., Delaware (USA)2 Bäderland Bayerische Rhön GmbH & Co. KG, Bad Kissingen1 Other companies/shelf companies Energiezentrale Universitätsklinikum Gießen GmbH, Giessen Kinderhort Salzburger Leite gemeinnützige Gesellschaft mbH, Bad Neustadt a. d. Saale KLINIK “HAUS FRANKEN” GMBH Bad Neustadt/Saale i. L., Bad Neustadt a. d. Saale Marburger Ionenstrahl-Therapie Betriebs-Gesellschaft mbH, Bad Neustadt a. d. Saale Psychosomatische Klinik GmbH Bad Neustadt/Saale, Bad Neustadt a. d. Saale PTZ GmbH, Marburg RHÖN-KLINIKUM Energie für Gesundheit GmbH, Bad Neustadt a. d. Saale1 RHÖN-Innovations GmbH, Bad Neustadt a. d. Saale RK Klinik Betriebs GmbH Nr. 35 i. L., Bad Neustadt a. d. Saale Wolfgang Schaffer GmbH i. L., Bad Neustadt a. d. Saale 100.0 –35,693 1,722 100.0 100.0 13 308 100.0 1,500 –8 –12 0 100.0 4,864 –357 100.0 100.0 0 0 4 4 0.1 8.8 15 7 4,044 –4,725 13.6 542 11 10.2 9,037 –949 25.0 12.2 1,290 –52 –196 69 HOSPIZ MITTELHESSEN gemeinnützige GmbH, Wetzlar1 Inovytec Medical Solutions Ltd., Hod Hasharon (Israel)2 Seniorenpflegeheim GmbH Bad Neustadt a. d. Saale, Bad Neustadt a. d. Saale1 Telesofia Medical Ltd., Tel Aviv (Israel)2 1 Figures according to annual financial statements of 31 December 2021. 2 Figures according to annual financial statements of 31 December 2021, converted at closing/average exchange rate on 31 December 2022. 1 The company claims the exemptions pursuant to section 264 (3) HGB from preparing notes and, to the extent required by law, from preparing a management report as well as disclosure. RHÖN-KLINIKUM AG | Annual Report 2022 133

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Other disclosures Leases within the Group 9.3 Standard IFRS 16 defines a lease as a contract which conveys the right to use an asset for a period of time in exchange for consideration. Within the Group, the modified retroactive approach was applied. Numerous property leases contain renewal options. Investment property 9.3.2 The Group lets residential space to employees, office and commercial space to third parties (e. g. cafeteria), as well as premises to doctors cooperating with the hospital and to joint laboratories as part of cancellable operating leases. For leases with a term of twelve months maximum amounting to € 0.1 million (previous year: € 0.1 million) as well as for leases relating to low-value assets in the amount of € 0.3 million (previous year: € 0.4 million), no rights of use and no lease liabilities are recognised within the Group of RHÖN-KLINIKUM AG. The lease rates are recognised as before within the income statement. Interest expenses from leases amounting to € 0.2 million (previous year: € 0.2 million) in financial year 2022. Further details on leases are provided in sections 6.2, 6.17 and 6.21.3. 9.3.1 Obligations of lessees Under leases, the Group mainly rents copier and printer systems as well as laboratory equipment. In the Group, there is a principle of always acquiring ownership of operating assets. in € million Liabilities from leases – minimum lease payments Due in subsequent year Due in two to five years Due in five years Future financing costs under leases Present value of liabilities under leases in € million Present value of liabilities under leases Due in subsequent year Due in two to five years Due in five years 2022 2021 2.9 5.1 0.7 8.7 –0.2 8.5 3.1 6.5 0.9 10.5 –0.3 10.2 2022 2021 2.9 5.6 – 8.5 3.1 7.1 – 10.2 RHÖN-KLINIKUM AG | Annual Report 2022 The most significant operating lease contracts by amount stem from the letting of property to third parties. The largest item in absolute terms is the letting of a property to a nursing home operator. Based on the provisions of IFRS 13.97, fair value is calculated for the assets to be stated according to IAS 40. The fair value determined in this regard cannot be observed on an active market nor can be derived from a quoted market price and are thus classified to Level 3 of the fair value hierarchy of IFRS 13. The fair value is determined using a capitalised value approach in which the corresponding components of the income cost approach such as gross profit, expected return on land value and standard land value are used as input factors. On the basis of the capitalised value of potential earnings, no material differences between the fair value of the properties and their carrying amounts shown below are seen. For this reason, no external fair value expertise was obtained. Since the lease agreement was terminated by the operator of the retirement and nursing home in financial year 2021, the useful life was adjusted in the previous year to the termination notice period. Rental income of € 0.4 million (previous year: € 0.4 million) was generated in financial year 2022. Based on the higher depreciation, the operating costs for the investment properties amounted to € 1.0 million in the financial year (previous year: € 1.0 million). They are accounted for entirely by properties with which rental income was generated. in € million Cost 1 Jan. Additions Disposals 31 Dec. Cumulative depreciation 1 Jan. Depreciation Disposals 31 Dec. Balance sheet value as at 31 Dec. 2022 2021 Total Total 5.0 0.0 0.0 5.0 3.7 1.0 0.0 4.7 0.3 5.0 0.0 0.0 5.0 2.8 0.9 0.0 3.7 1.3 135

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Other disclosures The members of management in key positions as well as close family relatives are treated as related parties. The Board of Management of RHÖN-KLINIKUM AG, the members of the Supervisory Board, as well as the members of management in key positions of a parent company were included among the members of management in key positions. Direct and indirect parent companies are the companies specified under Note 1 “General information” as well as Dr Bernard große Broermann. In the year under review, members of the Supervisory Board of RHÖN-KLINIKUM AG, or companies and entities related with these as well as companies within the meaning of IAS 24, rendered the following services at arm’s length terms: in € ’000 Related party Companies as defined by IAS 24 Nature of services Dr Bernard große Broermann Asklepios Kliniken Konzern of which Asklepios Kliniken GmbH & Co. KGaA AgenDix – Applied Genetic Diagnostics – Gesellschaft für angewandte molekulare Diagnostik mbH Prof. Dr Gerhard Ehninger (until 15 January 2021) Peter Berghöfer Hafid Rifi Marco Walker (from 9 March 2021) Regina Dickey (from 31 August 2021) Dr Cornelia Süfke (from 31 August 2021) Dr Jan Liersch (from 23 September 2022) Prof. Dr Bernd Griewing Eugen Münch Purchase of services and medical products Purchase of services and medical products Laboratory services Supervisory board activity at an affiliated company Supervisory board activity at an affiliated company Supervisory board activity at an affiliated company Supervisory board activity at an affiliated company Supervisory board activity at an affiliated company Supervisory board activity at an affiliated company Employee expenses, medical treatments Fee for services Expenses 2022 2021 8,519 2,773 4,027 2,127 – 4 2 3 4 3 1 1 5 2 3 1 1 – 207 693 29 656 As in the previous year, the expenses were recognised in the income statement under the item “Materials and consumables” as well as the item “Other expenses”. As in the previous year, no impairments were to be recognised in financial year 2022. RHÖN-KLINIKUM AG | Annual Report 2022 137

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Other disclosures As at the balance sheet date of 31 December 2022, the following trade receivables existed: in € ’000 Related party Companies as defined by IAS 24 Nature of services Dr Bernard große Broermann Asklepios Kliniken Group of which Asklepios Kliniken GmbH & Co. KGaA Services, pharmacy services and medical products Services and medical products Dr Stefan Stranz Medical services Receivables 2022 2021 1,091 283 0 0 0 1 The employee representatives on the Supervisory Board employed at RHÖN-KLINIKUM AG or its subsidiaries received the following remuneration within the scope of their employment contracts in the past financial year: in € ’000 Peter Berghöfer Regina Dickey Peter Ducke Prof. (apl.) Dr med. Leopold Eberhart Dr med. Martin Mandewirth PD Dr med. Thomas Pillukat Oliver Salomon Fixed Profit-linked Total 2022 Total 2021 215 51 32 129 177 147 57 808 6 1 1 0 2 14 1 25 221 52 33 129 179 161 58 833 211 48 38 192 156 169 56 870 The above costs are shown under employee benefit expenses in the income statement. RHÖN-KLINIKUM AG | Annual Report 2022 139

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Other disclosures The total payments of the Board of Management break down as follows: in € ’000 Incumbent member of Board of Management Base salary (fixed remuneration) Fringe benefits Total One-year variable remuneration Management profit sharing Total payments/total remuneration 1 Remuneration granted and owed in financial year. in € ’000 Incumbent member of Board of Management (Chairman of the Board of Management from 1 November 2022) Prof. Dr Tobias Kaltenbach Remuneration earned in financial year Inflow1 2022 in % 2021 in % 2022 (min.) 2022 (max.) 2022 in % 2021 in % 83 7 90 42 132 63 5 68 32 100 0 0 0 0 0 n. a. n. a. n. a. n. a. n. a. 83 7 90 0 90 83 7 90 42 132 83 7 90 0 90 92 8 100 0 100 0 0 0 0 0 n. a. n. a. n. a. n. a. n. a. Dr Stefan Stranz (Member of the Board of Management) Remuneration earned in financial year Inflow1 2022 in % 2021 in % 2022 (min.) 2022 (max.) 2022 in % 2021 in % Base salary (fixed remuneration) Fringe benefits Total One-year variable remuneration Management profit sharing2 Total payments/total remuneration 500 43 543 125 668 75 6 81 19 100 500 43 543 158 701 71 6 77 23 100 500 43 543 0 543 500 43 543 250 793 500 43 543 158 701 71 6 77 23 100 500 43 543 83 626 80 7 87 13 100 1 Remuneration granted and owed in financial year. 2 For the management profit sharing bonus for 2022, a target achievement ratio of 50% was assumed. RHÖN-KLINIKUM AG | Annual Report 2022 141

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Other disclosures in € ’000 Former member of Board of Management Base salary (fixed remuneration) Fringe benefits Total One-year variable remuneration Management profit sharing Total payments Pension expense1 Total remuneration (Member of the Board of Management until 31 October 2022) Prof. Dr Bernd Griewing Remuneration earned in financial year Inflow2 2022 in % 2021 in % 2022 (min.) 2022 (max.) 2022 in % 2021 in % 160 17 177 840 1,017 89 14 2 16 76 92 8 192 12 204 1,008 1,212 159 14 1 15 74 89 11 160 17 177 840 1,017 89 160 17 177 1,090 1,267 89 1,106 100 1,371 100 1,106 1,356 160 17 177 840 1,017 1,025 2,042 8 1 9 41 50 50 192 12 204 1,008 1,212 0 100 1,212 16 1 17 83 100 0 100 1 Pension expenditure includes past service cost according to IAS 19. 2 Remuneration granted and owed in financial year. RHÖN-KLINIKUM AG | Annual Report 2022 143

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Other disclosures 9.6 Declaration of Compliance with the German Corporate Governance Code By joint resolution of the Supervisory Board and the Board of Manage- ment of RHÖN-KLINIKUM AG of 15 December 2022, the Company made the declaration pursuant to section 161 of the German Stock Corporation Act (AktG) regarding the application of the German Corporate Governance Code in financial year 2022. It has been published on the website of RHÖN-KLINIKUM AG and thus made available to the general public. 9.7 Disclosure of the fees recognised as expenses (including reimbursement of outlays and excluding VAT) for the statutory auditors In financial year 2022, expenses resulting from fees for statutory auditors amounting to € 0.9 million (previous year: € 0.8 million) were incurred Group-wide. A breakdown of these fees (including outlays and excluding VAT) by service rendered is provided below: nearly € 850 million at the Giessen and Marburg sites to safeguard optimum healthcare delivery to people in the region, the quality of research and teaching as well as job security. The agreement with the Federal State of Hesse in connection with the financing of the services to be rendered for research and teaching at the Group’s university hospitals from 2017 provided for investment commitments in the amount of € 100.0 million until 2021. Already as at the balance sheet date of 31 December 2021, these investment obligations were fully met. There are also further obligations relating to building refurbishments and extension measures at the Giessen and Marburg sites which were initially due to be completed by 31 December 2024. With the White Paper (Zukunftspapier) signed at the end of February 2023, investment projects under the agreement from 2017 were modified and the time limits for meeting the investment obligations adjusted. The time limits for meeting these investment obligations are now in the time frame between 31 December 2024 and 31 December 2028. in € ’000 Fees for auditing financial statements Fees for other statutory auditing services Fees for tax advice Fees for other services 2022 2021 771 121 0 0 892 726 91 5 3 825 The White Paper Plus (Zukunftspapier Plus) signed at the end of February 2023 between the Federal State of Hesse, RHÖN -KLINIKUM AG, Asklepios Kliniken GmbH & Co. KGaA, Universitätsklinikum Gießen und Marburg GmbH (UKGM) as well as the universities with their faculties of medicine provides for the granting of investment funds in the amount of € 529 million for UKGM and further investment obligations to be financed from own funds over the next ten years in the amount of € 259 million as of 1 January 2023. The fees for the other statutory auditing services essentially cover certificates for hospital legislation purposes as well as for review of the separate non-financial report. The tax advisory services include fees for support services in the preparation of tax declarations and in the assessment of tax matters. Other services relate to fees for project-related advisory services. Of the total fee (excluding VAT), no fees are attributable to other statutory auditors who are not auditors of the consolidated financial statements. Events after the reporting date 9.8 In the negotiations with the Federal State of Hesse on the implementation of the Letter of Intent signed in January 2022 relating to the grant of investment funding as well as enhancing what is referred to as separate accounting, agreement was reached on the Future White Paper Plus (Zukunftspapier Plus) at the end of February 2023. Over the next ten years, the Federal State of Hesse and Universitätsklinikum Gießen und Marburg (UKGM) want to invest At the same time, the agreement provides for numerous provisions on further matters, including an obligation to reinvest profits of UKGM during this period, provisions in the event of a change in control, as well as a prohibition on outsourcing and the exclusion of redundancies. The guarantee to take over apprentices continues to apply. What is equally important for healthcare delivery and science is a concept for establishing joint ventures to be agreed between Universitätsklinikum Gießen und Marburg GmbH (UKGM) and the two universities making it possible to better translate research findings to clinical practice. The finance volume of € 60 million will be provided by UKGM. These funds are to be used to support the whole range of projects from early identification of areas of potential (scouting) right through to feasibility (proof of concept), thus making it possible to bridge the gap between clinical research and patients. Moreover, there are clear provisions regarding procedures for appointments and the terms of new appointments for teaching staff of both universities working at Universitätsklinikum Gießen und Marburg GmbH. This will make it possible to attract and recruit top researchers to Hesse. RHÖN-KLINIKUM AG | Annual Report 2022 145

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Corporate bodies of RHÖN-KLINIKUM AG Irmtraut Gürkan Alsbach, Dipl.-Volkswirtin (economist) PD Dr med. Thomas Pillukat Bad Neustadt a. d. Saale, MD Also a member of the Supervisory Board of: – Charité Universitätsmedizin Berlin, Berlin Other mandates: – Eurotransplant International Foundation, Leiden, Netherlands (Member of the Supervisory Board) – Stiftung Alice-Hospital vom Roten Kreuz zu Darmstadt, Darmstadt (Member of the Board of Trustees) – Universitätsspital Basel, Basel, Switzerland (Member of the Board of Directors) – Georg-August-Universität Göttingen, Göttingen (member of the Foundation Council) – Universitätsmedizin Göttingen, Göttingen (deputy chairman of the Foundation Committee) – Biolife Germany AG, Heidelberg Christine Reißner Sülzfeld, merchant Oliver Salomon Bad Berka, nurse Dr jur. Cornelia Süfke Hamburg, Legal Counsel (from 2 March 2022) Also a member of the Supervisory Board of: – Universitätsklinikum Gießen und Marburg GmbH, Giessen – Asklepios Kliniken GmbH & Co. KGaA, Hamburg Kai Hankeln Business address Hamburg, Chief Executive Officer of Asklepios Kliniken GmbH & Co. KGaA Marco Walker Business address Hamburg, Chief Operating Officer of Asklepios Kliniken GmbH & Co. KGaA Also a member of the Supervisory Board of: – Asklepios Fachklinikum Stadtroda GmbH, Stadtroda (Chairman of the Supervisory Board) – MEDICLIN Aktiengesellschaft, Offenburg Also a member of the Supervisory Board of: – MEDICLIN Aktiengesellschaft, Offenburg – Meierhofer Aktiengesellschaft, Munich – Universitätsklinikum Gießen und Marburg GmbH, Giessen Dr med. Martin Mandewirth Oberelsbach, Facharzt für Herzchirurgie (MD, specialist in heart surgery) RHÖN-KLINIKUM AG | Annual Report 2022 147

CONSOLIDATED FINANCIAL STATEMENTS | Responsibility statement Responsibility statement We assure to the best of our knowledge that based on the account- ing principles to be applied the consolidated financial statements of RHÖN-KLINIKUM AG give a true and fair view of the net assets, financial position and results of operations of the Group, and that the Group Management Report presents the business performance including the business results and the situation of the Group in such a way as to give a true and fair view of the same as well as a descrip- tion of the material risks and opportunities involved in the probable development of the Group of RHÖN-KLINIKUM AG. Bad Neustadt a. d. Saale, 14 March 2023 RHÖN-KLINIKUM Aktiengesellschaft THE BOARD OF MANAGEMENT Prof. Dr Tobias Kaltenbach Dr Stefan Stranz Dr Gunther K. Weiß RHÖN-KLINIKUM AG | Annual Report 2022 149

CONSOLIDATED FINANCIAL STATEMENTS | Independent Auditor’s Report Please refer to Section 3.2 in the notes to the consolidated finan- cial statements for information on the accounting policies applied. Disclosures on the amount of revenue can be found in the notes to the consolidated financial statements under Section 5.1. THE FINANCIAL STATEMENT RISK The revenue recognised in the Company’s consolidated financial statements relates essentially to hospital services, which represent EUR 1,446.1 million. As at the reporting date, for settlement reasons revenue is based on a series of management assumptions which involve estimate uncer- tainties. As the budget negotiations relevant for performance often take place towards the end of the financial year, the remunerated service volumes are estimates as at the reporting date. Also at the reporting date, a revenue correction is made based on manage- ment’s estimate of the change rate (case deductions) of the German Medical Service of the Health Insurance Funds public entity (MD). Due to the complexity of the judgements described, there is the risk for the consolidated financial statements that revenue is not appropriately assigned to the relevant reporting period. There is also the risk that the support payments received during the year as a result of the coronavirus SARS CoV-2 pandemic are overstated in revenue. OUR AUDIT APPROACH In order to evaluate the appropriateness of the revenue recognised as at the reporting date, we gave consideration to the Company’s established processes to recognise revenue from hospital services performed and the revenue corrections required, and we verified the methodological approach of management in making the revenue corrections. To audit the appropriate accrual of revenue, we exam- ined the design, establishment and effectiveness of the internal controls in respect of case processing (dual control principle). During our audit, using (among other things) the contractual docu- mentation presented to us and other correspondence and based on a risk-oriented deliberate sample, we obtained an overview relating to the status of the various budget agreements of the hospitals in the RHÖN-KLINIKUM Group on the reporting date and the respective remunerated service volumes. For the budget negotiations which had not been concluded as at the reporting date, we assessed the appropriateness of the estimated budget amounts, the costs relevant to the care budget and the revenue compensation. We also comprehended the management assumptions on the service volumes to be remunerated as at the reporting date based on the detailed information provided to us. In order to assess the estimation accuracy, we compared the revenue corrections with the outcome of the negotiations with the health insurers from previous years (taking into account the transition to outsourced diagnosis related groups). With respect to the revenue compensation, we also examined the process for calculating the revenue compensation, including the costs relevant to the care budget, in addition to the reconciliations in the context of the revenue validation based on the respective performance statistics of patient management and the underlying agreements. In doing so, we also validated the implementation of the legal regulations. In reference to possible corrections by the MD, we gave consider- ation to the process for determining the service volumes (codes applied) and for determining the relevant corrections and assessed the appropriateness of the estimates on revenue corrections as a result of audits by the German Medical Service of the Health Insur- ance Funds. We also assessed the accounting-related documentation for the amount and timing of recognised revenue from compensation payments due to the coronavirus SARS CoV-2 and evaluated the calculations associated with the compensation methodology. OUR OBSERVATIONS The assumptions underlying revenue recognition are appropriate. – Recoverability of goodwill Please refer to Section 2.4.1 in the notes to the consolidated financial statements for information on the accounting policies applied and the assumptions used. Disclosures on the amount of goodwill can be found in Section 6.1 of the notes to the consolidated financial statements. RHÖN-KLINIKUM AG | Annual Report 2022 151

CONSOLIDATED FINANCIAL STATEMENTS | Independent Auditor’s Report In preparing the consolidated financial statements, management is responsible for assessing the Group's ability to continue as a going concern. They also have the responsibility for disclosing, as appli- cable, matters related to going concern. In addition, they are responsible for financial reporting based on the going concern basis of accounting unless there is an intention to liquidate the Group or to cease operations, or there is no realistic alternative but to do so. Furthermore, management is responsible for the preparation of the group management report that, as a whole, provides an appropriate view of the Group's position and is, in all material respects, con- sistent with the consolidated financial statements, complies with German legal requirements, and appropriately presents the oppor- tunities and risks of future development. In addition, management is responsible for such arrangements and measures (systems) as they have con sidered necessary to enable the preparation of a group management report that is in accordance with the applicable Ger- man legal requirements, and to be able to provide sufficient appro- priate evidence for the assertions in the group management report. The Supervisory Board is responsible for overseeing the Group's financial reporting process for the preparation of the consolidated financial statements and of the group management report. Auditor's Responsibilities for the Audit of the Consolidated Financial Statements and of the Group Management Report Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and whether the group management report as a whole provides an appropriate view of the Group’s position and, in all material respects, is consistent with the consolidated financial statements and the knowledge obtained in the audit, complies with the German legal requirements and appro- priately presents the opportunities and risks of future development, as well as to issue an auditor’s report that includes our opinions on the consolidated financial statements and on the group manage- ment report. Other Information Management and/or the Supervisory Board are/is responsible for the other information. The other information comprises the following components of the group management report, whose content was not audited: – the Group's separate non-financial report, which is referred to in the group management report, and – the corporate governance statement referred to in the group management report. The other information also includes the remaining parts of the annual report. The other information does not include the consolidated financial statements, the group management report information audited for content and our auditor's report thereon. Our opinions on the consolidated financial statements and on the group management report do not cover the other information, and consequently we do not express an opinion or any other form of assurance conclusion thereon. In connection with our audit, our responsibility is to read the other information and, in so doing, to consider whether the other infor- mation – is materially inconsistent with the consolidated financial state- ments, with the group management report information audited for content or our knowledge obtained in the audit, or – otherwise appears to be materially misstated. Responsibilities of Management and the Supervisory Board for the Consolidated Financial Statements and the Group Management Report Management is responsible for the preparation of consolidated financial statements that comply, in all material respects, with IFRSs as adopted by the EU and the additional requirements of German commercial law pursuant to Section 315e (1) HGB and that the con- solidated financial statements, in compliance with these require- ments, give a true and fair view of the assets, liabilities, financial position, and financial performance of the Group. In addition, man- agement is responsible for such internal control as they have deter- mined necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud (i.e., fraudulent financial reporting and misappropriation of assets) or error. RHÖN-KLINIKUM AG | Annual Report 2022 153

CONSOLIDATED FINANCIAL STATEMENTS | Independent Auditor’s Report a basis for the prospective information, and evaluate the proper derivation of the prospective information from these assump- tions. We do not express a separate opinion on the prospective information and on the assumptions used as a basis. There is a substantial unavoidable risk that future events will differ materially from the prospective information. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. We also provide those charged with governance with a statement that we have complied with the relevant independence require- ments, and communicate with them all relationships and other matters that may reasonably be thought to bear on our indepen- dence, and where applicable, the actions taken or safeguards applied to eliminate independence threats. From the matters communicated with those charged with gover- nance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor’s report unless law or regulation precludes public disclosure about the matter. Other Legal and Regulatory Requirements Report on the Assurance on the Electronic Rendering of the Consolidated Financial Statements and the Group Management Report Prepared for Publication Purposes in Accordance with Section 317 (3a) HGB We have performed assurance work in accordance with Section 317 (3a) HGB to obtain reasonable assurance about whether the r endering of the consolidated financial statements and the group management report (hereinafter the “ESEF documents”) con- tained in the electronic file “RhoenKlinikumAG.zip” (SHA256 hash value: 7e9ca46036a373da24bd01b6a12c3ad560cb63ed36b871 befc4443c12c4f272e) made available and prepared for publication purposes complies in all material respects with the requirements of Section 328 (1) HGB for the electronic reporting format (“ESEF format”). In accordance with German legal requirements, this assurance work extends only to the conversion of the information contained in the consolidated financial statements and the group management report into the ESEF format and therefore relates neither to the information contained in these renderings nor to any other information contained in the file identified above. In our opinion, the rendering of the consolidated financial state- ments and the group management report contained in the electron- ic file made available, identified above and prepared for publication purposes complies in all material respects with the requirements of Section 328 (1) HGB for the electronic reporting format. Beyond this assurance opinion and our audit opinion on the accompanying consolidated financial statements and the accompanying group management report for the financial year from 1 January to 31 De- cember 2022 contained in the “Report on the Audit of the Consol- idated Financial Statements and the Group Management Report” above, we do not express any assurance opinion on the infor mation contained within these renderings or on the other information contained in the file identified above. We conducted our assurance work on the rendering of the con- solidated financial statements and the group management report contained in the file made available and identified above in accor- dance with Section 317 (3a) HGB and the IDW Assurance Standard: Assurance Work on the Electronic Rendering of Financial Statements and Management Reports Prepared for Publication Purposes in Accordance with Section 317 (3a) HGB (IDW AsS 410 (06.2022)). Our responsibility in accordance therewith is further described below. Our audit firm applies the IDW Standard on Quality Management 1: Requirements for Quality Management in Audit Firms (IDW QS 1). The Company's management is responsible for the preparation of the ESEF documents including the electronic rendering of the con- solidated financial statements and the group management report in accordance with Section 328 (1) sentence 4 item 1 HGB and for the tagging of the consolidated financial statements in accordance with Section 328 (1) sentence 4 item 2 HGB. In addition, the Company’s management is responsible for such internal control that they have considered necessary to enable the preparation of ESEF documents that are free from material intentional or unintentional non-compliance with the requirements of Section 328 (1) HGB for the electronic reporting format. RHÖN-KLINIKUM AG | Annual Report 2022 155

SUMMARY REPORT OF RHÖN-KLINIKUM AG | Balance sheet and income statement Balance sheet and income statement BALANCE SHEET INCOME STATEMENT in € million in € million 31 Dec. 2022 31 Dec. 2021 2022 2021 Assets Intangible assets Property, plant and equipment Financial assets Fixed assets Inventories Receivables and other assets Securities, cash, and cash equivalents Current assets Prepaid expenses Deferred tax assets in € million Liabilities Subscribed capital/ issued capital Capital reserve Retained earnings Net distributable profit Shareholders’ equity Contribution to finance fixed assets Provisions Liabilities 7.6 270.0 579.8 857.4 6.7 162.0 277.0 445.7 2.2 7.0 Revenues Changes in services in progress Other operating income Materials and consumables used Employee benefits expense Depreciation Other operating expenses Operating result Investment result Finance result Taxes 8.8 283.0 602.9 894.7 7.0 119.7 258.6 385.3 2.0 7.6 1,312.3 1,289.6 Net profit for the year Profit carried forward from previous year Net distributable profit 31 Dec. 2022 31 Dec. 2021 307.9 0.0 12.6 92.6 156.9 23.4 43.0 4.6 2.8 5.3 1.9 10.8 0.0 10.8 282.3 0.2 8.8 93.0 152.0 22.9 35.8 –12.4 5.3 6.0 –8.7 7.6 193.2 200.8 The Annual Financial Statements as at 31 December 2022 and the Management Report for financial year 2022 of RHÖN-KLINIKUM Aktiengesellschaft were issued by KPMG AG Wirtschaftsprüfungs- gesellschaft with an unqualified auditor’s report. They are published in the Companies Register. The Annual Financial Report can be obtained from the Company on request. 167.4 589.0 201.0 10.8 968.2 10.2 44.7 289.2 167.4 589.0 0.1 200.8 957.3 11.0 48.8 272.5 1,312.3 1,289.6 RHÖN-KLINIKUM AG | Annual Report 2022 157

FURTHER INFORMATION | Independent assurance practitioner’s report regarding the combined separate non-financial report Independent assurance practitioner’s report1 To RHÖN-KLINIKUM Aktiengesellschaft, Bad Neustadt a. d. Saale We have performed a limited assurance engagement on the combined separate non-financial report as well as the by reference qualified part “Basic Characteristics of the RHÖN-KLINIKUM Group” of RHÖN-KLINIKUM Aktiengesellschaft, Bad Neustadt a. d. Saale, (further “Company” or “RHÖN-KLINIKUM”), which consists of the sections of the Corporate-Social-Responsibility-Report (further „combined sep- arate non-financial report”) marked with a tick (√) for the period from January 1 to December 31, 2022. Management’s Responsibility The legal representatives of RHÖN-KLINIKUM Aktiengesellschaft are responsible for the preparation of the combined separate non- financial report in accordance with §§ 315c in conjunction with 289c to 289e HGB (Handelsgesetzbuch, German Commercial Code) and with Article 8 of REGULATION (EU) 2020/852 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of June 18, 2020 on the establish- ment of a framework to facilitate sustainable investment and amend- ing Regulation (EU) 2019/2088 (further „EU Taxonomy Regulation“) and the supplementing Delegated Acts as well as the interpretation of the wordings and terms contained in the EU Taxonomy Regula- tion and in the supplementing Delegated Acts by the Company as disclosed in Section “Reporting according to EU taxonomy” of the combined separate non-financial report. This responsibility of the legal representatives of the company includes the selection and application of appropriate methods to prepare the combined separate non-financial report and the use of assumptions and estimates for individual disclosures which are reasonable under the given circumstances. Furthermore, the legal representatives are responsible for the internal controls they deem necessary for the preparation of the combined separate non- financial report that is free from material misstatements, whether due to fraud (manipulation of the combined separate non-financial report) or error. tatives have included a description of their interpretation in Section “Reporting according to EU taxonomy” of the combined separate non-financial report. They are responsible for its tenability. Due to the innate risk of diverging interpretations of vague legal concepts, the legal conformity of these interpretations is subject to uncertainty. Independence and Quality Assurance on the Part of the Auditing Firm In performing this engagement, we applied the legal provisions and professional pronouncements regarding independence and quality assurance, in particular the Professional Code for German Public Auditors and Chartered Accountants (in Germany) and the quality assurance standard of the German Institute of Public Auditors (Institut der Wirtschaftsprüfer, IDW) regarding quality assurance requirements in audit practice (IDW QS 1). Practitioner’s Responsibility It is our responsibility to express a conclusion on the combined separate non-financial report based on our work performed within a limited assurance engagement. We conducted our work in the form of a limited assurance engage- ment in accordance with the International Standard on Assurance Engagements (ISAE) 3000 (Revised): “Assurance Engagements other than Audits or Reviews of Historical Financial Information”, published by IAASB. Accordingly, we have to plan and perform the assurance engagement in such a way that we obtain limited assurance as to whether any matters have come to our attention that cause us to believe that the combined separate non-financial report of the Com- pany for the period from January 1 to December 31, 2022 has not been prepared, in all material respects, in accordance with §§ 315c in conjunction with 289c to 289e HGB and with the EU Taxonomy Regulation and the supplementing Delegated Acts as well as the interpretation of the wordings and terms contained in the EU Tax- onomy Regulation and in the supplementing Delegated Acts by the legal representatives as disclosed in Section “Reporting according to EU taxonomy” of the combined separate non-financial report. The EU Taxonomy Regulation and the supplementing Delegated Acts contain wordings and terms that are still subject to substantial uncertainties regarding their interpretation and for which not all clarifications have been published yet. Therefore, the legal represen- As the assurance procedures performed in a limited assurance engagement are less comprehensive than in a reasonable assurance engagement, the level of assurance obtained is substantially lower. 1 Our engagement applied to the German version of the combined separate non-financial report. This text is a translation of the Independent Assurance Report issued in German, whereas the German text is authoritative. RHÖN-KLINIKUM AG | Annual Report 2022 159

FINANCIAL CALENDAR TERMINE FÜR AKTIONÄRE UND ANALYSTEN 2023 30 March Results press conference: publication of 2022 Annual Financial Report 11 May Publication of interim report for the quarter ending 31 March 2023 7 June Annual General Meeting 10 August Publication of half-year financial report as at 30 June 2023 9 November Publication of interim report for the quarter ending 30 September 2023 – analyst conference RHÖN-KLINIKUM AG DISCLAIMER The information provided in this Report does not constitute an offer or solicitation to buy shares of RHÖN-KLINIKUM AG. All reasonable care has been taken to ensure that the content of this Report was accurate on the date of publication. However, RHÖN-KLINIKUM AG accepts no warranty that all information is complete, accurate and up to date. Any investment in shares of RHÖN-KLINIKUM AG must be made on the basis of the information contained in the Company’s prospectus in its authorised form. Although as a general rule we employ the masculine form for better readability when referring to persons, this form covers all persons of the respective group, irrespective of their (social) gender and gender identity. Postal address: 97 615 Bad Neustadt a. d. Saale Germany Visitors’ address: Salzburger Leite 1 97 616 Bad Neustadt a. d. Saale Germany T. +49 (0)9771 650 F. +49 (0)9771 974 67 Internet: rhoen-klinikum-ag.com Email: rka@rhoen-klinikum-ag.com Published on 30 March 2023 This Annual Report is also available in German. Annual Report on the internet en.rhoen-klinikum-ag.com/annual-report